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Approximately 5-8% of Americans are affected by some type of autoimmune disease.  The 
current standard of care for these patients involves pharmacologic therapy to induce systemic 
immunosuppression, which carries significant side effects.  There is a need for therapies that 
effectively restore immune-mediated tolerance towards the body, but do not cause inappropriate 
immunosupression. 
The following dissertation details the synthesis, characterization, and performance of 
tolerogenic dendritic cells (DC), as well as the exosomes that they secrete.  Exosomes are small 
(40-100 nm) membrane-bound microvesicles produced by reverse budding of the membrane of 
the multivesicular endosome in DC, as well as many other cell types.   DC were transduced with 
adenoviral vectors expressing target genes in order to manipulate their function.  After 
transduction, DC and their exosomes were examined for the ability to modulate disease-induced 
inflammation in the NOD mouse model of type 1 diabetes and the delayed-type hypersensitivity 
(DTH) model. 
DC transduced with an IL-4 expressing vector are capable or preventing the onset of 
hyperglycemia when administered to 12-weeks-old and 12-16 week-old prediabetic mice.  
Treated mice demonstrate modulation of T-cell mediated β-cell autoimmunity, including reduced 
insulitis, increased FoxP3 expression in the islet-draining lymph nodes, and Th2 skewing of 
islet-antigen induced cytokine secretion profile.   
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We further demonstrate that transduction of DC with adenoviral vectors expressing 
indoleamine 2,3-diooxygenase (IDO) and CTLA-4-Ig are efficient means to generate IDO+ DC 
in vitro, and that these DC effectively reduce paw swelling in the DTH model of antigen-specific 
inflammation.  The exosomes secreted by these IDO+ DC contain IDO protein, and suppress 
DTH responses at a level comparable to their parental DC in a manner dependent on B7-1 and 
B7-2.  To confirm the role of B7 costimulatory molecules on tolerogenic DC and exosomes, we 
further demonstrate that B7-1 and B7-2, but not PD-L1 or PD-L2, are required for in vivo 
suppressive activity of rIL-10 treated DC and their secreted exosomes. 
 This endeavor has increased the knowledge regarding therapeutic DC and exosomes.  We 
have demonstrated strategies to generate tolerogenic DC and exosomes, as well as factors that 
are required for their activity in vivo. 
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1.0  INTRODUCTION 
The immune system is responsible for defense of the body against harmful pathogens by 
mounting appropriate responses to eliminate the problematic organism.  However, another 
important task of the immune system is differentiating harmless from injurious stimuli in order to 
prevent unnecessary and potentially dangerous reactions to innocuous organisms or parts of the 
host organism.  Indeed, a wide variety of research has elucidated mechanisms whereby the 
immune system senses exogenous and endogenous signals and differentiates whether there is 
potential for harm [1]. 
As professional antigen presenting cells (APC), dendritic cells (DC) play a central role in 
determining whether the response of the immune system will be directed towards immunity or 
tolerance.  DC are derived from CD34+ hematopoeitic stem cells, and are distributed throughout 
all tissues where they convey antigen from peripheral sites into the secondary lymphoid tissues.  
They are equipped with numerous pattern recognition receptors, such as TLR4 (recognizes the 
bacterial product lipopolycaccharide (LPS), extracellular breakdown products of hyaluron, and 
endogenous Hsp70), TLR2 (recognizes DNA CpG sequences), which enable them to detect 
danger signals released by injured cells as well as pathogens [2].  The cumulative effect of the 
signals received by APC results in alterations in their final maturation state when they present 
antigen to T cells within the secondary lymphoid tissues.  
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APC encountering antigen in the presence of danger signals will stimulate immunity.  It 
is important to consider that these danger signals are not exclusively delivered by infections, but 
can occur in the setting of cell injury, setting up a vicious cycle in pathological conditions such 
as autoimmune diseases whereby inflammation-induced cell damage contributes to the ongoing 
inflammation.  DC maturation occurs following binding of damage-associated molecular patterns  
(DAMPs) or pattern-associated molecular patterns (PAMPs) bind their pattern-recognition 
receptor on the DC, which results in intracellular signaling changes within the DC.  This results 
in the release of inflammatory cytokines from DC, such as IL-12 and interferon-α (IFN-α) [3, 4]. 
Mature DC are characterized by an increase in major histocompatibility complex (MHC) 
presentation of antigen, as well as upregulation of costimulatory molecules such as B7-1 (also 
known as CD80) and B7-2 (also known as CD86), as well as an increase in the production of 
inflammatory cytokines and chemokines [5, 6].  Mature DC are capable of priming T cell 
responses towards infections and tumors [7, 8], and polarizing T cell immunity towards the Th1, 
Th-17, or Th2 pathways [9-11].   
In the absence of pathogenic threats, DC continue to sample antigen from the body.  In 
these conditions, however, the antigen will be derived from the repertoire of host-expressed 
proteins, and therefore in these conditions it is critical that DC prevent unnecessary autoimmune 
activation that may lead to self-destructive autoimmunity.  DC play critical roles in both 
thymically-developed central tolerance, as well as peripheral tolerance.  In the thymus, thymic 
and peripheral DC present self-derived antigen to thymocytes during clonal deletion, a process 
whereby autoreactive T cells are eliminated [12, 13].  However, there is a growing body of 
evidence that demonstrates that in most individuals some autoreactive T cells persist despite the 
process of central deletion. Therefore, the mechanisms of peripheral tolerance are necessary to 
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prevent the development of autoimmune disease.  These mechanisms are varied and include: 
immunological ignorance of the antigen, apoptosis (or peripheral deletion) of the self-reactive 
clone following exposure to excessive levels of antigen, induction of anergy, or induction of 
regulatory T cells [14].   A subset of peripheral DC termed ‘tolerogenic’ DC play a significant 
role in the final two mechanisms, and a growing body of evidence suggests tolerogenic DC play 
important roles in autoimmune disease, allergy, and transplantation, among others and will be 
discussed in further detail below. 
The goal of this research is to investigate the therapeutic potential of DC which have 
been engineered to be tolerogenic using adenoviral vectors, as well as the exosomes secreted by 
these DC, for the treatment of type 1 diabetes.  The methods used to generate tolerogenic DC and 
evaluated in this proposal have the potential to be therapeutic in numerous different autoimmune 
diseases.  However, the proposed work will be carried out focusing on two model systems.  The 
NOD mouse, which spontaneously develops type 1 diabetes will be employed as it is the most 
widely accepted model of type 1 diabetes.  The delayed-type hypersensitivity model, which is a 
model of acute, antigen-specific inflammation, will be used in order to allow us to conduct some 
mechanistic studies that would not currently be possible in the NOD model.   The specific aims 
of the studies detailed in this dissertation are summarized below.   
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1.1 SPECIFIC AIMS 
1.1.1 Specific Aim 1: Investigate the therapeutic benefit of DC genetically-engineered to 
overexpress IL-4 (DC/IL-4) and exosomes secreted by these DC (exo/IL-4) for type I 
diabetes using a late-stage NOD mouse model, and elucidate the cellular mechanisms by 
which they modulate inflammation. 
We have previously demonstrated that DC transduced with an adenoviral vector expressing 
Interleukin-4 (IL-4) reduce disease severity in murine models of arthritis and hypersensitivity, 
and are able to prevent diabetes onset when administered at early ages to NOD mice [15, 16]. 
Further, it is known that the β cell destruction in type 1 diabetes is mediated by a Th1-type T cell 
response, with CD8+ T-cells being responsible for the majority of beta cell damage.  Successful 
therapies alter this process significantly, therefore we will investigate the effect of DC and 
exosome therapy on T cell function and phenotype.   
Hypothesis 1.1: DC/IL-4 and exo/IL-4 have the ability to reduce pancreatic insulitis and prevent 
the onset of hyperglycemia in NOD mice following adoptive transfer at 12 weeks of age. 
Hypothesis 1.2: Increased levels of IL-4 in secondary lymphoid organs following adoptive 
transfer of DC/IL-4 and exo/IL-4 will result in alteration of the pathogenic Th1/Th2 balance seen 
in the NOD mouse. 
Hypothesis 1.3: Mice treated with DC/IL-4 as well as exo/IL-4 will have higher levels of 
regulatory T cells following treatment when compared to untreated mice. 
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1.1.2 Specific Aim 2: Examine the molecular mechanisms conferring the in vivo 
suppressive effects of DC and exosomes.  
The experiments for Aim 2 will be conducted using a delayed-type hypersensitivity (DTH) 
model in C57Bl/6 mice instead of the NOD model because of the greater availability of knockout 
strains in a C57Bl/6 background. Our greater understanding of which modifications and doses of 
DC and exosomes are effective in this model make DTH a superior model compared to the NOD 
mouse to determine specific molecules that are necessary for the suppression of inflammation 
using our DC and DC-derived exosome treatments.  There has been increasing evidence to 
support the importance of indoleamine-(2,3)-diooxygenase IDO expression in DC in establishing 
peripheral tolerance [17, 18].  However, efficient means to generate IDO+ DC in vitro have yet 
to be elucidated. Further studies demonstrating a requirement for B7-1 in the surface of 
exosomes for function in vitro drew our attention to the role of costimulatory molecules on 
exosomes, and our previous studies in the DTH model indicate that the in vivo suppressive 
activity of exosomes rely on the presence of MHC II and FasL on the exosome surface [19, 20].  
These previous studies led us to suspect a role for direct interaction between exosomes and T 
cells in vivo, which may translate into a requirement for B7 family costimulatory molecules for 
in vivo suppressive activity.    Therefore in the studies that follow we will examine: 
Hypothesis 2.1: Adenoviral transfer of IDO results in a population of DC capable of 
suppressing DTH responses and secreting exosomes which also reduce DTH. 
Hypothesis 2.2: Adenoviral transfer of CTLA-4-Ig to DC results in IDO+ DC and 
exosomes which are capable of suppressing DTH. 
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Hypothesis 2.3: Expression of B7-1 and B7-2 T cell costimulatory molecules are critical 
on the surface of DC and DC-derived exosomes for in vivo regulation of inflammation in the 
DTH model. 
Hypothesis 2.4:  Loss of PD-L1 and PD-L2 T cell costimulatory molecules, which tend 
to confer inhibitory signals to T cells, on DC and DC-derived exosomes will result in loss of 
ability to abrogate paw swelling in the DTH model. 
1.2 TOLEROGENIC DENDRITIC CELLS 
1.2.1 Mechanisms of DC-Mediated Tolerance 
Dentritic cells (DC) are best known for their ability to induce strong innate and adaptive immune 
responses towards foreign antigen in vivo.   However, a growing body of evidence illustrates that 
DC also play an important role in the maintenance of tolerance.  This functional dichotomy is 
governed chiefly by the phenotypic state of the DC itself, as DC are equipped with multiple 
mechanisms by which they are able to sense the status of their surrponding microenvironment.  
These mechanisms include the toll-like receptors (TLR) 2, 3, 4, 7, and 9, which sense a wide 
variety of microbial and endogenous danger signals and sense DC maturation into a 
phenotypically mature and stimulatory state [21].   In the absence of danger signals, DC continue 
to sample self-antigen, but in this setting there are low costimulatory signals expressed on the 
DC, resulting in poor stimulation of naïve T cells [22, 23].  Studies have further elucidated the 
mechanisms by which tolerogenic DC function in vivo, and these will be discussed in further 
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detail below.   Collectively, these data imply that tolerogenic DC possess a number of redundant 
mechanisms whereby they can regulate tolerance. 
1.2.1.1 Induction of Regulatory T Cells 
DC can promote the induction of regulatory T cells, including the thymically-differentiated 
CD4+CD25+ as well as the T regulatory-type 1 cells (Tr1 cells), which are CD4+ and express 
IL-10 and TGF-β.  Repetitive in vitro stimulation with immature, allogeneic DC leads to the 
production of non-proliferating, IL-10-producing Treg cells [24]. Further, DC can expand 
antigen-specific CD4+CD25+ Treg populations by triggering their division [25].  DC cultured in 
the presence of IL-10, IL-4 or TGF-β assume a regulatory phenotype that is capable of 
generating CD4+ and CD8+ regulatory T cells [26].  Further pharmacologic treatment to induce 
tolerogenic DC have also been shown to produce DC capable of inducing T cell populations.  
When injected into mice post-transplant, rapamycing treated-DC promote the infiltation of 
allografts with regulatory T cells, which prevents vasculopathy and promotes graft tolerance 
[27].   
1.2.1.2 Induction of T cell Apoptosis or Anergy 
DC with reduced maturation characteristic have reduced ability to induce T cell anergy or 
apoptosis, or induce antigen-specific hyporesonsiveness.  These DC are typically have reduced 
expression of the costimulatory molecules, which can be achieved by selective blockade, culture 
with cytokine cocktails, or treatments with pharmacological agents.    
 Evidence from use of CTLA-4-Ig further demonstrates the importance of B7 molecule 
expression on tolerogenic DC.  CTLA-4-Ig can directly compete with CD28, which activates T 
cells, for binding of B7-1 and B7-2 on DC [28].  However, independently of this function it also 
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functions through reverse cell signaling into B7-1 and B7-2 containing cells to result in the 
upregulation of IDO [29].  IDO is a tryptophan metabolizing enzyme which indirectly inhibits T 
cell activation and induces T cell apoptosis [30].  Therefore, in addition to the costimulatory 
molecule profile of the DC, its expression of IDO is also a critical factor in mediating tolerance. 
 Another important feature of DC interactions with reactive T cells is the cytokine profile 
which they secrete. T cell polarization is driven by the cytokine profile present on initial antigen 
presentation, with high production of IL-12 being critical for the development of Th1-driven 
responses [31]. DC transduced to express IL-10, TGF-β, or CTLA-4-Ig induce Ag-specific T-
cell hyporesponsiveness, inhibits the generation of cytotoxic T cells, and promotes Th2-skewing 
of donor responses [32]. 
1.2.1.3 Negative Selection Within the Thymus 
Although central tolerance is less of a target for ex vivo modified DC, nonetheless there are a few 
studies supporting a role for manipulation of central tolerance via manipulation of DC.  Thymic 
DC are located in the medulla, and both these DC and the medullary epithelium are capable of 
deleting autoreactive T cells [33].  This selection is dependent on the expression of antigen 
within MHC complexes [34].  Little work has been done to date to explore the ability of 
modified DC to manipulate central tolerance. A recent study as examined the ability to transduce 
thymic DC in vivo following thymic injection with recombinant adenoviral vectors, and find that 
this reduced disease severity in a model of bacterial peritonitis [35].  Further, intrathymic 
injection of alloantigen prevents allograft rejection in rate in a manner dependent on the presence 
of host APC within the thymus [36].   
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1.2.2 Phenotype of Tolerogenic DC 
DC maturation is a critical component in determining the ability of DC to either confer tolerance 
or stimulate immunity.  Maturation of DC occurs in response to extracellular stimuli, and allows 
DC to tailor their responses according to their microenvironment.  Table 1 contrasts some 
important phenotypic differences between immature and mature DC [14, 21].  Mature DC are 
potent stimulators of T cell proliferation and polarization toward the Th1 or Th17 phenotype, 
whereas immature DC can differentiate both naturally-occurring and IL-10 secreting CD4+ Tr1-
type regulatory T cells in vivo [37].  Diverse strategies have been examined as methods to 
generate tolerogenic DC in vitro, and these will be reviewed in detail in the following section.  
Variations in the phenotype of the resultant DC occur based on the type of treatment used in 
culture with the DC.  In general, the aim of these “tolerizing” regimens is to produce DC which 
mimic the phenotype, and more importantly, the function, of immature DC closely. Specifically, 
the tolerogenic DC should not stimulate T cell responses but rather should promote tolerance 
[14, 21, 38].  This can be accomplished by controlling the culture conditions of DC with 
cytokines and pharmacologic agents in a manner which renders them maturation-resistant, or by 
providing DC with a single predominant feature, such as overexpression of IL-10, which results 
in a DC which induce tolerance when administered in vivo. 
1.2.3 In Vitro Generation of Tolerogenic DC for Adoptive Transfer Therapy 
Various methods to manipulate DC in vitro in order to generate tolerogenic DC have been tried.   
The goal of these ex vivo manipulations is to generate a maturation-resistant, immature DC 
phenotype that is capable of conferring tolerance when used in patients.  Although the desired  
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Table 1: Phenotypic Characteristics of Immature and Mature DC 
                                       Immature DC                         Mature DC 
 
 
MHC I 
MHC II 
 
B7 family  
B7-1 
B7-2 
PD-L1 
PD-L2 
ICOSL 
CD40 
 
Adhesion molecules 
ICAM-1 
LFA-1 
 
NF-κB 
 
Polarizing cytokines 
IL-12 (Th1) 
IL-1β (Th17 ad Th2) 
IL-6 (Th17) 
TNF-α (Th17) 
 
Indoleamine 2,3-
dioxygenase (IDO) 
 
 
 
Low                                     High 
Low                                     High 
 
 
Low                                     High 
Low                                     High 
Present/High                       High 
Present/High                       High 
Low/Present                        High 
Low                                     High 
 
 
High                                    Low 
High                                    Low 
 
Cytoplasmic                  Activated/Nuclear 
 
 
none/low                       produced 
none                              produced 
none                              produced 
none                              produced 
 
 
High                                    Low 
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phenotype of these DC is described in more detail above, they tend to express MHC, with a low 
ratio of costimulatory to inhibitory signals and low overall production of Th1-polarizing 
cytokines such as IL-12.  Various methods have been used to induce the desired DC phenotype, 
and are detailed below. 
1.2.3.1 Treatment with Biological Molecules 
Following exposure to a number of cytokines, DC may assume a tolerogenic phenotype.  
Multiple studies have demonstrated a role for both IL-10 and TGF-β1 in the generation of a 
tolerogenic DC phenotype.  These two cytokines have been of particular interest because they 
are both expressed by the Tr1-type regulatory T cell, and have been shown to mediate tolerance 
in multiple models, including autoimmunity and transplant [39].  Treatment of DC with IL-10 
does not alter the ability of DC to take up soluble antigen, however, the antigen presentation 
properties of the DC are altered significantly as the levels of MHC II and costimulatory 
molecules are decreased on the surface of IL-10 treated DC [40, 41].  However, if IL-10 is 
applied to DC culture at early stages to monocyte cultures, it can inhibit DC maturation and 
promote the differentiation of macrophages [42, 43].   TGF-β treatment of DC resulted in 
induction of a CD8+ regulatory T cell population and amelioration of disease in mice with 
experimental autoimmune encephalomyelitis [44].  Recent studies have shown that autocrine 
TGF-β signaling in CD8+ DC results in sustained activity of IDO, whereas treatment of CD8- 
DC with TGF-β can result in IDO induction and induction of a regulatory DC phenotype [45]. 
 In addition to IL-10 and TGF-β, other biological compounds have been used to generate 
tolerogenic DC.  A large number of studies have looked at the ability of 1α,25(OH)2D3, the 
active form of vitamin D3, to generate tolerogenic DC in vitro. 1α,25(OH)2D3–treated DC were 
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LPS-induced maturation resistant, and alloreactive CD4+ T cells secreted lower levels of IFN-γ 
in mixed lymphocyte reactions with the 1α,25(OH)2D3-treated DC compared to control DC [46]. 
Vitamin D analog treatment of DC has further been shown to have aa significant impact on the 
gene expression within treated DC via binding to the Vitamin D receptor [47]. 
Recently, vasoactive intestinal peptide (VIP)-treated DC have been shown to express IL-
10, maintain low levels of costimulatory molecules CD40, CD80, and CD86 upon stimulation 
with LPS, and induce Tr1 CD4+ and CD8+ CD28- CTLA-4+ CD8+ regulatory T cells when co-
incubated with naïve cells [48, 49].   Other biological molecules that have been demonstrated to 
have an effect on DC phenotype include prostaglandin E2, histamine, β2 agonists, glucosamine, 
N-acetyl-ι-cysteine, and cobalt protoporphyrin, which induces expression of heme-oxygenase-1 
[38]. 
1.2.3.2 Treatment with Pharmacologic Agents 
Many immunomodulatory drugs have been investigated for their ability to modify DC function 
in vitro or in vivo [50].  Conventional immunosuppressive medications, such as cyclosporin A, 
FK506, rapamycin and corticosteroids have been tested.  Cyclosporin A and tacrolimus (FK506) 
are both calcineurin inhibitors. Cyclosporin A inhibits NF-κB translocation, thereby inhibiting 
the production of IL-6 and IL-12, and maturation of the DC [51].  FK506 inhibits T-cell 
allostimulatory capacity of the DC, however, the phenotype of DC following treatment with 
FK506 seems to vary based on the culture conditions [52].  Glucocorticoid treatment inhibits the 
production of inflammatory cytokines such as IL-6, TNF-α, and IL-12p40 in response to ligation 
of CD40 or treatment with LPS, whereas the secretion of IL-10 remained unchanged [53].  
Treatment of DC with LF15-0195, a deoxyspergualine analog prevents the TNFα/LPS 
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dependent translocation of NF-κB in DC, and these DC are promoted the differentiation of Th2 
cell phenotype from naïve T cells in vitro [54].  Finally, rapamycin treatment of DC cultures 
reduces DC maturation and T cell stimulatory capacity both in vitro and in vivo, and the 
rapamycin treated DC have enhanced ability to stimulate the activity of CD4+ CD25+ FoxP3+ T 
regulatory cells [27, 55].  It is hoped that in the setting of transplantation, treatment of DC ex 
vivo with immunomodulatory pharmacotherapy could have the potential to spare patients form 
the severe systemic side effects associated with these agents, while administration of the 
tolerogenic DC generated could help to establish tolerance to the autograft.  
1.2.3.3 Manipulation of Gene Expression 
A number of viral and non-viral methods have been examined for the delivery of transgenes to 
DC, and are outlined in Table 2. 
Different strategies have been employed to generate tolerogenic DC using gene therapy 
techniques.  The majority of the studies focus on the delivery of a transgene with known 
biological properties, such as cytokines whose immunomodulatory properties are known to direct 
T cells responses away from the Th1 pathway.  Some examples include IL-10, TGF-β, IL-4, or 
CTLA-4-Ig [32].  Other studies have focused on the inhibition of pro-inflammatory signals, such 
as siRNA targeting of IL-12, and the use of an NF-κB decoy to prevent DC maturation [56-58]. 
One potential pitfall to the use of viral vectors, however, is that the viruses themselves 
interact with the DC and are capable of modulating the DC characteristics .  Each virus has its 
own characteristics of interaction with the host immune system which must be taken into 
account, in addition to the inherent advantages and disadvantages of the vector itself for gene  
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Table 2: Successful strategies for gene transfer to DC. 
Viral Vectors: 
 
Adenovirus [16, 62-68] 
Retrovirus [32, 69, 70] 
Lentivirus [71, 72] 
Vaccinia Virus [73] 
Herpes Simplex Virus [74, 75] 
 
Non-Viral: 
 
Plasmid DNA [76] 
Antisense oligonucleotides [77] 
NF-κB decoy oligodeoxyribonucleotides [58, 78] 
siRNA [56, 57] 
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transfer purposes.  In the case of adenoviral vectors, invasion of the viral capsid in to the cell, as 
well as recognition of viral CpG motifs by pattern recognition receptors trigger a characteristic 
process of DC maturation [59, 60].  This results in the upregulation of costimulatory molecules, 
increased production of pro-inflammatory cytokines, and is dependent on NF-κB translocation 
[61].  Therefore, great care must be taken to assess the phenotype of DC following viral 
transduction. 
 
1.3 EXOSOMES 
Exosomes are small vesicles approximately 60-100 nm in diameter originating in the 
multivesicular endosome.  These small vesicles were originally described as part of the process 
of reticulocyte maturation [79], as it was originally theorized that the exosomal pathway was an 
method to eliminate waste protein from the cell during the reticulocyte maturation process.  
However, it has since been demonstrated that antigen presenting cells such as dendritic cells 
(DC) secrete exosomes from the cell surface and further, these exosomes are functional and 
capable of modulating the immune responses [80].  In addition to DC, many other cell types 
including B cells [81], mast cells [82], macrophages, intestinal epithelial cells [83], and multiple 
malignant cell types including melanoma [84], lymphoma [85], and mesotheliomas produce 
exosomes [86]. Exosomes have been documented in human serum [87], urine [88], 
bronchoalveolar fluid [89], and malignant effusions [90, 91]. Following further investigation 
since their discovery in the 1980s, a growing body of literature demonstrates that exosomes are a 
mechanism for cell-cell communication. 
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Within the multivesicular endosome, exosomes are formed by reverse budding of the late 
endosomal membrane, resulting in membrane-bound vesicles that contain cytosolic proteins and  
expose the extracellular domain of membrane proteins.  Thery et al. demonstrated using mass-
spectroscopy that DC-derived exosomes carry MHC I and II, as well as the B7 costimulatory 
molecules B7-1 and B7-2 [92]. In addition, DC derived exosomes carry other molecules that 
modulate immune responses, such as FasL [93, 94], TNFα [95], and, PD-L1 [96].  Adhesion 
molecules, such as integrins, tetraspannins, and lactadherin (MFG-E8) are also present on the 
exosomal membrane, and heat shock proteins (hsc70, hsp82), enzymes, and cytoskeletal proteins 
have been demonstrated within the intraexosomal space [92].  To date, studies have 
demonstrated the presence of hundred of different proteins within exosomes, and the function of 
these are only beginning to be explored [80, 97]. Exosomes also carry biomarkers such as tumor 
antigens Mart-1 and MelCAM-1 [84, 98] and proteins associated with acute kidney failure [99], 
suggesting that exosomes are possible targets for diagnostic testing. Additionally, exosomes 
carry mRNA and microRNA, and studies have demonstrated that the mRNA carried in exosomes 
is functional and capable of inducing changes in gene expression in recipient cells [100]. 
1.3.1 Exosomes play a role in the regulation of immune responses. 
Recently exosomes have been shown to be involved in regulating certain biological processes, 
although the mechanisms by which this immune regulation can occur remain unclear.  Exosomes 
may transfer proteins to cells through membrane fusion. Mack et al. reported that microvesicles 
can transfer the co-receptor for HIV, CCR5, from CHO cells to CD4+ T cells that do not carry 
CCR5, rendering the cells susceptible to HIV infection [101].  Secretion of IL-1ß, a pro-
inflammatory cytokine, can occur via microvesicles that appear to be similar or identical to 
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exosomes [102].  In addition, it has been suggested that exosomes are able to transfer MHC class 
II molecules through clustering and fusion to follicular DCs, cells that normally are devoid of 
MHC Class II [103].   
There is also evidence that exosomes also are internalized and processed by certain types 
of DC, in a mechanism similar to the uptake of apoptotic cell debris.  DC-derived exosomes are 
internalized via endocytosis by specific DC subsets both in cell culture as well as in vivo [104].  
This internalization is dependent on LFA-1 on recipient CD8+ DC, which interacts with ICAM-1 
on exosomes to mediate uptake and internalization of exosomes [105].  MFG-E8 (lactadherin) 
associates with the phosphatidyserine rich membrane of exosomes via its C1C2 domain, and can 
mediate exosomes phagocytosis following binding off its N-terminal domain to αvβ3 and αvβ5 
integrins on macrophages [106]. However, this interaction seems to be redundant as loss of 
lactadherin on the exosome surface does not inhibit the ability of cells to  internalize exosomes.  
Furthermore, novel phosphatidylserine recptors, Tim1 and Tim4 (T cell immunoglobulin domain 
and mucin domain proteins 1 and 4) have been identified on activated phagocytes, which may 
play an additional role in the capture of exosomes [107]. How internalized exosomes regulate 
DC activity is unclear, but it is possible that the endocytosed exosomes are able to back fuse with 
the multivesicular endosome to mediate transfer of MHC class II and other proteins to the cell 
surface.   
A number of studies have examined the ability of exosomes to interact directly with T 
cells.  As, with DC, LFA-1 addresses DC-derived exosomes to T cells in a manner that is 
dependent on T cell activation and not T cell receptor specificity [108].  Furthermore, exosomes 
produced by DC pulsed with tumor antigen peptides were able to stimulate an anti-tumor 
response in mice as efficiently as the DC themselves [109].  There are conflicting reports 
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regarding the ability of DC derived exosomes to stimulate T cells directly in vitro.  The ability of 
the exosomes carrying a specific MHC class I peptide to stimulate T cell proliferation in vitro 
required non-pulsed dendritic cells, suggesting that exosomes are able to transfer the MHC class 
I complex to the DC [110].  Others have demonstrated that pregnancy derived exosomes are 
capable of interacting directly with T cells and down regulating zeta-chain signaling [93].  
Tumor-derived vesicles have been shown to inhibit T cell function in a manner dependent on 
FasL [94].   
1.3.2 Exosomes Can Suppress Immune Responses.  
There have been numerous reports in the literature that describe an ability of exosomes for 
different sources to suppress immune responses, although the mechanism of exosome-mediated 
suppression remains unclear in many cases.  Small particles produced by rat intestinal epithelial 
cells cultured in the presence of INF-gamma and digested ovalbumins were able to induce a low 
level of antigen specific tolerance after injection.  Similarly, small particles isolated from the 
serum of rats fed ovalbumin (OVA) were able to suppress an OVA-specific delayed type 
hypersensitivity (DTH) response through a MHC-dependent mechanism [111].   These small 
vesicles isolated from rat serum, termed tolerosomes, appear to be similar or identical to 
exosomes and are MHC Class II+.  These results are similar to observations by our lab, which 
have shown that intra-dermal immunization with a specific antigen results in the generation of 
MHC Class II+ exosomes in the serum, able to suppress the DTH response following injection 
into the mouse footpad in an antigen-specific manner [19].  These results are consistent with the 
observation that placental-derived exosomes in the peripheral circulation of pregnant women 
induce apoptosis in T lymphocytes through a Fas/FasL, PD-L1/PD-1 and possibly IDO-
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dependent mechanism [93]. Similarly, certain T cell subsets and tumor cells generate exosomes 
that contain FasL on their surface able to stimulate T cell apoptosis [112, 113]. Moreover, high 
levels of tumor-derived FasL positive exosomes can be found in the serum of cancer patients and 
tumor-derived vesicles can modulate the phenotype and function of monocytes.  Thus exosomes 
derived from certain cell types, under certain conditions, are able to suppress the immune 
response.   
Consistent with the observations that exosomes can suppress the immune response, we 
have shown in both murine DTH and collagen induced arthritis (CIA) models that DC-derived 
exosomes are able to suppress the immune response [114, 115]. Moreover, it appears as if the 
genetic modification of the DC to express IL-4, vIL-10, FasL or IDO results in exosomes that are 
able to suppress the DTH response more effectively. The suppression of the immune response, at 
least in a murine DTH model, appears to be MHC class I independent, but MHC Class II, and 
Fas/FasL-dependent, although it seems that FasL is able to regulate the immune response 
through a non-apoptotic mechanism.  Taken together, the results examining immune regulation 
by exosomes suggests that exosomes derived from not only DC, but other cells types as well 
serve to regulate immune responses to foreign and possibly auto-antigens.   
Despite the interesting observations regarding the ability of immunosuppressive 
exosomes to regulate immune responses, very little is known about the requirements for their 
activity in vivo, or their exact mechanism of action. Therefore, it seems that DC-derived 
exosomes are a poorly characterized, but potentially highly relevant and clinically useful agent 
for the treatment of not only autoimmune diseases, but potentially cancer, allergy, and other 
diseases.  One possible advantage to the use of immunosuppressive exosomes for the treatment 
of autoimmune diseases, in contrast to immunosuppressive DC, is that exosomes are thought to 
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be unable to undergo phenotypic changes following administration.  In theory, an exosome 
purified from a tolerogenic DC should retain its “tolerogenic” potential following injection, 
unlike immature DC that could undergo maturation if they receive stimulatory signals from the 
microenvironment in vivo.  This may therefore make them more attractive as a therapeutic agent, 
if their efficacy and safety can be demonstrated in a convincing manner.  However, there may be 
disadvantages to using exosomes as therapies, such as low product yield or product purity 
compared to the relatively high doses that may be required to achieve a therapeutic effect.  
Therefore, since both DCs and exosomes have advantages and disadvantages, we will investigate 
both as portential therapies in these studies. 
1.4 TYPE I DIABETES  
Type 1 diabetes (T1D), also known as insulin-dependent diabetes mellitus, is recognized 
as a rapidly growing health threat worldwide. The CDC estimates that 15,000 young people in 
the United States per year are diagnosed with T1D, with 19 new cases per 100,000 youth each 
year [116]. Worldwide, the incidence of diabetes varies greatly by geographical location, ranging 
from 0.1 per 100,000/year in China and Venezuela to 40.9 per 100,000/year in Finland, and has 
been increasing since the 1950’s [117].  From 1990-1999, the incidence of T1D worldwide 
increased 2.8%, confirming the need for new methods to address this growing public health 
concern [117]. 
T1D is a polygenic autoimmune disease characterized by the T-cell-mediated destruction 
of insulin-producing β cells in the pancreatic islets of Langerhans, leading to insulin 
deficiency. T1D is a chronic disease that is known to exist for years in a preclinical phase before 
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the classic manifestations are observed. This preclinical phase, known as insulitis, is 
characterized by the infiltration of leukocytes into the islets. The actual onset of diabetes occurs 
after most β cells have been killed, resulting in insulin deficiency and secondary hyperglycemia 
[118].  
Autoreactive T-cells that react specifically to β cell expressed proteins or auto-antigens 
such as glutamic acid decarboxylase (GAD) and insulin play a key role in the pathogenesis of 
T1D.  β cell autoantigens are processed by antigen presenting cells (APC), including 
macrophages, dendritic cells, and B cells, in the pancreatic islets. APC then present processed 
peptides to autoreactive CD4+ T cells, cells which have survived negative selection in the 
thymus, in the pancreatic lymph node (PLN) and other peripheral draining lymphoid organs. 
Activated autoreactive CD4+ T cells secrete cytokines and activate β cell-specific cytotoxic 
CD8+ T cells (CTL). The activated CTL then migrate to the islets where the actively kill β-cells 
as well as produce inflammatory cytokines, which activate more CTL, as well as macrophages, 
further contributing to the destruction of β cells [119, 120]. In general, TH1 cytokines, such as 
IL-2, IFN-γ, and TNF-α, promote T1D development, while TH2 or TH3 cytokines, such as IL-4, 
IL-10, and TGF-β, prevent T1D onset. β cell death is the direct result of cytotoxic cytokines and 
other agents released from CTL and macrophages, including IL-1β, TNF-α, IFN-γ, oxygen free 
radicals, granzyme and perforin. Additionally, Fas and TNF receptors, known as death receptors, 
mediate apoptosis, thus playing a role in β cell death [119].  
T1D patients are rarely diagnosed before onset of hyperglycemia and loss of the majority 
of pancreatic β cells, and typically present with symptoms associated with a combination of low 
insulin levels and high blood glucose, including: weight loss, polyuria, polydipsia, and 
polyphagia.  This is a significant challenge to immunotherapy strategies, both because it is 
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difficult to predict which at-risk patients will ultimately develop diabetes, but also because very 
little βcell mass remains at the time of diagnosis.  Due to the current lack of therapies which 
halt the progression of βcell destruction, T1D patients ultimately require lifelong insulin 
replacement therapy, and are at risk of developing significant complications associated with 
hyperglycemia, including: retinopathy, neuropathy, nephropathy, and accelerated peripheral 
vascular and coronary artery disease.  A major focus of existing therapy is to improve the insulin 
therapy regimens of T1D patients in order to prevent the onset or progression of secondary 
complications.   
1.4.1 Insulin Therapy for Type 1 Diabetes 
The Diabetes Control and Complications Trial (DCCT) was the first large-scale trial to 
demonstrate the beneficial therapeutic value of intensive insulin control compared to 
conventional insulin therapy on the development and progression of complications in patients 
with T1D [121].  In the intensive insulin control group, patients monitored their blood glucose 
≥4 times per day, and received insulin injections ≥3 times per day with the goal of achieving a 
target glycosylated hemoglobin (A1c) within the normal range (≤ 6.05%), wherea s patients in the 
conventional therapy group had no specific goal except to prevent hyperglycemia or 
hypoglycemia, and received 1-2 daily self-injections of insulin.  The baseline A1c for both 
groups was 9.1%, but at the conclusion of the study the intensive insulin therapy group’s mean 
A1c had decreased to 7.4% compared to no change in the conventional insulin therapy group. In 
the primary prevention cohort the risk of developing retinopathy was reduced by 76% (95% CI: 
62-85%) and in the secondary prevention cohort the progression of retinopathy was slowed by 
54% (95% CI: 14-67%) in the intensive insulin therapy groups.  Collectively, these studies laid 
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the groundwork for encouraging tight glycemic control in all diabetic patients in order to 
minimize the complications associated with hyperglycemia.   
However, there are still shortcomings which remain to this approach.  A major concern 
with the use of an intensive insulin regimen is the risk of severe hypoglycemic episodes, with 
accompanying risks of injury or neurological damage.  In the DCCT, the risk of severe 
hypoglycemic episodes was approximately three times greater in the intensive insulin therapy 
group compared to the conventional therapy group.  Additionally, the DCCT investigators 
observed a 33% increase in the mean adjusted risk of becoming overweight in the intensive 
therapy group compared to the conventional therapy group.  Furthermore, practical application of 
intensive insulin regimens is often difficult in clinical settings due to the relatively large 
resources needed for patient education as well as their fundamental dependence on patient 
motivation and compliance. Intensive regimens also require more frequent monitoring and 
insulin administration, and although the development of insulin pumps have made insulin 
administration more simple there is still significant daily time and care involved.  Finally, 
especially during adolescence some patients are not compliant with therapy, and during these 
times tight hyperglycemic control may be especially difficult [122].   
Several general fields of research have become prominent in the search for alternatives to 
lifelong insulin therapy for type I diabetics:  particularly islet transplantation to restore lost β cell 
mass and insulin production, and immunotherapy to establish tolerance and allow for 
endogenous β-cell regeneration. Although allogeneic islet transplantation has shown some 
evidence of success, the allo- and autoimmune response against the islets often leads to their 
destruction [123, 124].  Therefore patients receiving grafted islets require lifelong 
immunosuppressive therapy, which carries significant side effects.  Due to the need for lifelong 
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immunosuppression, whole-pancreas transplant is rarely performed alone, and more frequently 
performed in T1D patients undergoing kidney transplant for diabetic nephropathy.  The 
widespread applicability of both of these techniques is limited by the supply of islets from 
cadaveric donors, and in general both procedures have been offered only to T1D patients who 
have hypoglycemic unawareness, severe metabolic or secondary complications, or are unable to 
follow an insulin regimen [125]. Immunotherapy strategies, which promote tolerance toward the 
β cells, are currently an area of intense research because of their potential ability to save the 
patient’s own remaining β cell mass, to possibly allow for β cell regeneration or pancreatic islet 
transplant.  
1.4.2 Immunomodulatory Therapy for Type 1 Diabetes 
Over the past 30 years, significant efforts have been made to test the efficacy of 
immunomodulating therapies in T1D.  An ideal immunomodulating agent for diabetes would 
specifically halt β cell destruction without causing systemic immunosuppression or inhibiting the 
process of β cell regeneration.  It has been demonstrated in both humans and NOD mice that at 
the onset of clinical diabetes there is still significant residual β-cell mass, and early intervention 
with an effective immunotherapy during this period has the potential to restore tolerance and 
allow endogenous cells to regenerate the islets [126].  However, some immunosuppressive drugs 
used in common islet transplant protocols have been shown to inhibit spontaneous regeneration 
of β cell mass in vivo, and therefore drugs intended for this application must be carefully tested 
for their effects on β cell growth in vivo [127].  Two general approaches to immunomodulation 
have been tried in T1D: non-specific agents as well as islet antigen-specific approaches to 
promote tolerance to β cells.   
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Non-specific agents such as cyclosporine, methotrexate, anti-thymocyte globulin, and 
BCG vaccination have been tested for the prevention of T1D onset, and have proven 
unsuccessful either due to poor side effect profiles or lack of efficacy [128].  Recent trials of the 
anti-CD3 immunoglobulin have been promising, as patients treated with a single dose of the anti-
CD3 antibody had increased C-peptide responses to meals for 1 year or longer after treatment, 
reduced hemoglobin A1c levels, and reduced need for insulin supplementation [129]. However, 
there are also reports of side effects with anti-CD3, notably an influenza-like syndrome and 
Epstein-Barr viral mononucleosis [128].  Trials are currently underway investigating the use of 
rituximab, an anti-CD20 antibody that downregulates the B cell signaling of T cells.  In 
preclinical trials using NOD mice, rituximab was shown to prevent and reverse diabetes onset by 
altering the levels of diabetogenic T cells [130, 131].      
Preventative vaccination to self-antigens is an extremely attractive idea for the treatment 
of autoimmune diseases such as diabetes, but several hurdles remain before these therapies can 
be applied clinically.  First, an antigen-specific vaccination product must have an excellent safety 
profile, including the ability to reliably tolerize and never stimulate the recipient’s immune 
response towards autoimmunity.  Second, despite extremely promising preclinical results in the 
NOD model of T1D, the therapeutic efficacy of these products for diabetes have yet to be shown 
in clinical trials with diabetes patients.  For example, in the diabetes prevention trial (DPT-1), 
systemic or oral administration of insulin given to high-risk relatives of T1D patients had no 
efficacy in preventing diabetes onset when compared to matched control group [132].  Other 
trials examining the benefits of an intranasally administered insulin, as well as an intramuscular 
alum-Gad65 preparation, have shown some initial promise and work is ongoing to investigate the 
ultimate benefit of these methods [133, 134].  A recent clinical trial examining subcutaneous 
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injection of an Alum-GAD formulation showed a 15-month delay in the loss of secreted C-
peptide levels, but ultimately did not impact the insulin requirement of patients receiving therapy 
[135].  Therefore, although tolerance induction to islet-specific antigen remains an intriguing 
possibility, there has not been a convincing demonstration of the efficacy of this approach. 
Collectively, these studies illustrate the challenges facing scientists in finding appropriate 
immunotherapy for T1D.  At this point, it remains unclear which of these agents are the most 
beneficial at halting the progression of autoimmunity as many underlying aspects of the 
pathogenesis of T1D have yet to be elucidated.  An additional challenge in developing human 
therapies is the clinical heterogeneity of human disease compared to the homogeneity of inbred 
mouse models.  Indeed, many interventions that have prevented diabetes in preclinical models 
such as the NOD mouse ultimately prove unsuccessful as clinical therapy [136].   As a result of 
this dismaying fact, Roep, Atkinson, and von Herrath have suggested that results from animal 
models such and the NOD mouse and knockout strains be considered similarly to clinical case 
reports, and that prospective therapies should be verified in multiple animal models prior to 
transitioning into clinical studies [137]. 
1.4.3 Role of DC in Type 1 Diabetes 
Recent research is elucidating an important role for DC in the initiation and maintenance of 
autoimmunity in T1D and other autoimmune diseases [138].    This may in part be a consequence 
of defects in the DC themselves in autoimmune-prone individuals.  An increasing number of 
studies have demonstrated that in both T1D patients and the NOD mouse model the DC have 
defects which make them more prone to stimulate autoimmunity than tolerance [139].  DC from  
NOD mice have been demonstrated to have defects in their maturation status, as well as 
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hyperactive NF-κB signaling due to increased activity of the I-κB kinase activity [140, 141]. 
Further, DC from NOD mice have a defect in tryptophan catabolism in response to IFN-γ, which 
renders them less able to confer tolerence [142]. A small study in which T1D patients failed to 
mount appropriate antibody responses following administration of DC pulsed with experimental 
antigen seems to confirm the results seen in NOD mice, and suggests that T1D patients as well 
also have some defects in antigen-presentation ability of DC [143].  
Given the data to support the role of DC in mediating between immunity and tolerance, it 
is perhaps unsurprising to find that imbalanced DC function contributed to the pathogenesis of 
T1D.  Given the role DC play in regulating autoimmunity in the periphery, tolerogenic DC 
therapy is especially promising in autoimmune diseases such as T1D because it has the potential 
to reestablish antigen-specific peripheral tolerance.  
1.4.4 Tolerogenic DC Therapy for Type 1 Diabetes 
Dendritic cells have been of particular interest for applications in T1D because of their unique 
role in regulating T cell responses.  Both adenoviral and lentiviral gene transfer of IL-4 to DC 
have been shown to have protective effects in the NOD model of T1D [15, 72].   In 
collaboration, our lab has shown that DC transduced with an adenoviral vector expressing IL-4 
(DC/IL-4) are able to prevent the onset of disease in 5 and 10 week old NOD mice, and this was 
accompanied by an increase in the IL-4:IFN-γ and IL-10:IFN-γ cytokine expression rations 
within the pancreata of mice treated with DC/IL-4 [15].  Cruesot et al have demonstrated similar 
results using DC transduced with a lentivirus expressing IL-4, and further demonstrate that the 
ability of DC/sIL-4 to prevent diabetes onset required MHC II expression on the DC [72]. 
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Others have shown that modifying DC with an adenoviral vector encoding for galectin-1, 
a lectin with regulatory effects on T cells, could delete diabetogenic T cells in vivo [144]. 
Furthermore, non-viral approaches for transduction of DC have also been particularly successful.  
NF-κB decoy oligoneucleotide treatment of DC was shown to inhibit DC activation and 
maturation, inhibit the expression of CD40, CD80 (B7-1), and CD86 (B7-2) costimulatory 
molecules, and prevent the onset of diabetes in the NOD mouse model [145].  Further studies in 
NOD mice examining the ability of DC treated with antisense oligonucleotides directed at CD40, 
CD80 (B7-1) and CD86 (B7-2) costimulatory molecules have proven particularly successful, and 
these studies have progressed into clinical trials [77].  
To date, few proposed gene therapy strategies for T1D have progressed to the point of 
clinical trials.  However, a Phase 1 clinical trial to examine safety is currently ongoing using 
genetically modified DC in which antisense oligonucleotides (AS-ODN) targeting of mRNA for 
the costimulatory molecules CD40, CD80 (B7-1), and CD86 (B7-2) results in a tolerogenic DC 
phenotype with very low expression of the targeted costimulatory molecules.  In preclinical 
studies using the NOD mouse model of T1D, investigators demonstrated that the AS-ODN 
treated bone-marrow derived DC were able to delay the incidence of diabetes after a single 
injection, and observed that the AS-ODN treated DC resulted in an expansion of a 
CD4+CD25+CD62L+ regulatory T cell population [77]. It is believed that the lack of 
costimulatory molecules on the DC result in an anergizing signal to diabetogenic T cells, as well 
as expansion of regulatory T cells.  In the ongoing clinical study, autologous DC are generated 
from T1D patient’s leukocytes in vitro after harvest by leukapheresis.  The DC are cultured and 
engineered using the AS-ODN to CD40, CD80, and CD86 and then injected intradermally at a 
site distal to the pancreas to allow for DC migration into the lymph nodes.  At the time of 
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writing, the Phase I trial is currently ongoing and is focused on the safety of this approach in a 
patient population that is over 18 and has had insulin-dependent T1D for greater than five years 
[146].  If successful, the next step will be a Phase II trial focused on efficacy of treatment in 
newly-diagnosed T1D patients, fitting with the paradigm that early intervention with 
immunotherapies is most effective at saving any residual βcell mass. 
1.5 DELAYED TYPE HYPERSENSITIVITY 
There are four types of immune-mediated hypersensitivity reactions, which as a group cause 
significant disease burden.  Types I, II, and III are mediated by antibodies and can be 
distinguished from each other based on the type of antigen involved as well as the antibody class 
effecting the hypersensitivity response.  Type IV hypersensitivity reactions are T cell mediated 
and can be divided into three groups based on the T cell effector population.  A summary of the 
different types of hypersensitivity reactions can be found in Table 3. 
As shown in Table 3, DTH responses are mediated by CD8+ T cells and Th1 CD4+ T 
cells.  There are two phases to DTH responses: sensitization and elicitation (summarized in [147, 
148]).  During sensitization, resident cutaneous DC, termed Langerhan’s cells, take up antigen 
and migrate to the draining lymph node where they activate resident T cells, which generates a 
memory T cell response.  Subsequent migration of these antigen-specific memory T cells results 
in their distribution throughout the dermis.  During the elicitation phase of the DTH response, re-
exposure to the sensitizing antigen results in the release of cytokines such as IFN-γ and IL-17 
from memory T cells once recognized within the MHC complex.  This stimulates the release of 
inflammatory mediators from nearby keratinocytes, such as IL-1, IL-6, TNF-α , GM-CSF, and  
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Table 3: Coombs and Gell classification system for hypersensitivity reactions.*  
 
 Type I Type II Type III Type IV 
Example of 
hypersensitivity 
reaction 
Asthma, 
allergic 
rhinitis, 
systemic 
anaphylaxis  
Some drug 
allergies (ie: 
hemolytic 
anemia), 
chronic 
urticaria 
(involving 
antibody 
formation to 
FCεR1α) 
Serum 
sickness, 
Arthus 
reaction 
“classic” 
DTH (ie: 
tuberculin 
skin 
reaction), 
contact 
dermititis 
Contact 
dermitits 
Immune 
Reactant IgE 
IgG directed 
at antigens 
on tissues 
IgG directed 
at soluble 
antigens 
Th1 cells CTL 
Antigen Soluble  
Cell- or 
matrix- 
associated  
Soluble  Soluble  Cell-associated  
Effector 
Mechanism 
Mast-Cell 
Activation 
Complement, 
FcR+ Cells 
(Phagocytes) 
Complement, 
FcR+ Cells 
(Phagocytes) 
Macrophage 
Activation Cytotoxicity 
 
*Modified from “Janeway’s Immunobiology,” 7th ed. Murphy K, Travers P, Walport M (eds.), p 556. 
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chemokines, including CXCL8 (IL-8 in humans, MIP-2 in mice), CXCL11 (IP-9), CXCL10 (IP-
10), and CXCL9 (Mig).  These cytokines and chemokines induce the migration of additional 
monocytes and T cells into the lesion, amplifying the response.   
Both the classical DTH response (that seen in the purified protein derivative (PPD), or 
tuberculin skin test) and contact hypersensitivity are examples of delayed-type hypersensitivity 
reactions.  The classical DTH response is characterized by local erythema, induration and 
dermatitis.  It is used clinically for diagnostic purposes to test the presence of memory T cells to 
antigen, such as tuberculosis-derived antigen in the case of the tuberculin skin test.  Contact 
hypersensitivity is also characterized by erythema, but due to the more superficial distribution of 
antigen within the skin, indraepidermal abscesses and vesicle formation occurs.  Contact 
hypersensitivity can occur in response to a wide variety of antigens, but a classical example is 
the reaction that develops in response to the chemical pentadecacatechol produced by the poison 
ivy plant.  Finally, gluten-sensitive enteropathy, or celiac disease is also a form of delayed-type 
hypersensitivity which is directed at the gliadin antigen in wheat and other grains [149]. 
Given the multicellular and complex nature of the DTH response, it is perhaps not 
surprising that it can be disrupted at multiple points during both the sensitization and effector 
phases.  Induction of DTH can be impaired by deficiencies in antigen presentation, for example 
young male SJL mice do not initiate DTH responses, however following adoptive transfer of a I-
A+ Mac-1+ Mac-2- Mac-3+ cell population from female mice effective sensitization and normal 
DTH response occurs [150]. Splenic DC or Langerhan’s cells pulsed with KLH antigen ex vivo 
effectively prime mice for the DTH response when injected subcutaneously, but elicit the 
production of IgG and do not prime for the DTH response if injected intravenously [151, 152].  
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These studies illustrate the importance of APC and presentation of antigen in the local lymph 
nodes in order for sensitization to antigen to occur.   
Experiments comparing the ability of Th1 and Th2 cell subsets to participate in the 
effector phase of the DTH response have demonstrated that only Th1 cells elicit antigen-specific 
swelling [153], and that treatment with anti-IFN-γ blocking antibody is able to partially inhibit 
the DTH response [154, 155].  Due to its critical role in the production if IFN-γ, IL-12 is also 
necessary during the effector phase of the DTH response, and IL-12 knockout mice have 
significantly reduced DTH responses compared to wild-type controls [156].  Furthermore, 
exposure to UV radiation induces release of cytokines including IL-4 and IL-10, which can 
downregulate the levels of inflammation seen following challenge with sensitized antigen.  
Therefore, it is possible to limit either the sensitization and elicitation phases of the DTH 
response are effective methods to reduce the severity of disease. 
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2.0  DENDRITIC CELLS TRANSDUCED TO EXPRESS IL-4 PREVENT THE 
ONSET OF HYPERGLYCEMIA IN NOD MICE 
2.1 ABSTRACT 
Interleukin-4 (IL-4) has been demonstrated to be of significance in the pathogenesis and 
treatment of type 1 diabetes.  We and others have demonstrated that transduction of DC with IL-
4-expressing vectors can prevent the onset of diabetes in mice, however, there has yet to be a 
demonstration that DC transduced with IL-4 could reverse disease once defects in glucose 
homeostasis were demonstrated. DC were generated from the bone marrow of NOD mice and 
transduced with adenoviral vectors encoding soluble murine IL-4 (DC/sIL-4), a membrane-
bound IL-4 construct, or empty vector control. Female NOD mice were segregated into 
normoglycemic (<150mg/dL) and prediabetic groups (between 150 and 250 mg/dL) on the basis 
of blood glucose measurements, and randomized for adoptive transfer of DC or exosome therapy 
via a single i.v. injection. We find a single injection of DC/sIL-4, when administered to 
normoglycemic 12-week old NOD mice, is capable of significantly preventing disease onset.  
Furthermore, DC/sIL-4 also prevent the onset of disease in prediabetic NOD mice between the 
ages of 12-16 weeks of age. This requires the production of soluble IL-4, as DC transduced with 
the membrane-bound IL-4 vector had no therapeutic effect.  We further demonstrate that 
DC/sIL-4 significantly reduce islet mononuclear infiltration, and increase the expression of 
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FoxP3 in the pancreatic lymph nodes of a subset of animals.  Further, DC/sIL-4 treatment alters 
the antigen-specific Th2:Th1 cytokine profiles as detected by ELISPOT of splenocytes in treated 
animals as compared to control animals.  Exosomes derived from transduced DC were not 
capable of delaying diabetes onset when adoptively transferred to 12-week-old mice.  We 
conclude that adoptive transfer of DC transduced to express IL-4 offers significant promise for 
the treatment of autoimmune diabetes, and should be further developed. 
 
2.2 INTRODUCTION 
Type I diabetes (T1D) is a polygenic autoimmune disease characterized by destruction of 
insulin-secreting β-cells in the islets of Langerhans by a chronic inflammatory infiltrate.  In both 
humans and the nonobese diabetic (NOD) mouse, there is evidence that destructive insulitis is a 
T-cell mediated phenomenon, however, a growing body of evidence suggest that other cells 
types, such as NKT cells and antigen presenting cells (APC), play important roles in modulating 
disease onset and progression [138, 157, 158].  Although the exact pathogenesis remains unclear 
at this point, a combination of factors including a Th1-skewed CD4+ response as well as a 
deficiency of regulatory T cells are considered to be important hallmarks of the disease [157].   
A shift in the Th1/Th2 balance of T cell responses towards characteristic Th1 properties 
such as the release of IFN-γ plays an important role in the initiation and perpetuation of the 
inflammatory response in diabetes.  Furthermore, it has been demonstrated that shifting the 
balance of CD4+ responses towards a Th2-mediated response can have a therapeutic role.  
Numerous studies have demonstrated that delivery of exogenous IL-4, which polarizes T cell 
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responses towards a Th2 phenotype, has therapeutic potential for the treatment of type 1 
diabetes.  Systemic administration of recombinant IL-4 in NOD mice has been demonstrated to 
increase Th2-mediated responses in the spleen, thymus and pancreatic islets [159].  Transgenic 
NOD mice expressing IL-4 in the pancreatic islets are protected from the development of 
diabetes, and we have previously reduced onset of hyperglycemia in NOD mice after regulated 
delivery of IL-4 to pancreatic β cells following transduction with a double-stranded AAV vector 
expressing IL-4 under the control of the mouse insulin promoter [160].  Furthermore, we and 
others have shown that adoptive transfer of dendritic cell (DC) transduced ex vivo with IL-4-
expressing viral vectors traffic to the spleen and pancreatic lymph node of NOD mice and are 
capable of preventing diabetes onset [15, 72]. 
DC are APC which play a critical role in the development of central tolerance and the 
maintenance of peripheral tolerance by presenting foreign- or self-derived antigens in the context 
of instructive secondary signals to T cells.   Results from both NOD mice and patients with type 
1 diabetes document abnormalities in DC function such as increased NF-κB activity, decreased 
expression of indoleamine-2,3-dioxygenase, and altered costimulatory and cytokine secretion 
profiles [141, 142, 161, 162].  Further, DC are responsible for the presentation of islet-cell 
derived antigens to diabetogenic T cells, as well as to regulatory T cell populations within the 
pancreas and pancreatic lymph node [163-165].  Thus, there is considerable interest in the 
development of DC-based therapy for type 1 diabetes.  In addition to transduction with IL-4, 
others have demonstrated therapeutic benefit of other DC modifications, including: transduction 
with galectin-1, treatment with NF-κB-specific oligodeoxyribonucleotide, and antisense 
oligonucleotide blockade of costimulatory molecule expression [77, 78, 144].  At the time of 
writing, Phase I safety trials are currently underway testing costimulatory molecule-depleted DC 
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in type 1 diabetes patients, and trials of DC-based therapies in cancer patients have demonstrated 
the overall feasibility of ex vivo DC modification for immunotherapy [146, 166].  
In the NOD model, insulitis typically begins around 3-4 weeks of age, and diabetes 
occurs in 60-80% of female mice between 12-18 weeks of age depending on the housing 
conditions.   The NOD model has been used to test a large number of potential therapeutic 
interventions, many of which have ultimately had little to no clinical benefit [136].  One reason 
for this is that while many interventions are tested and successful in preventing diabetes onset in 
younger mice, they fail to prevent diabetes in older NOD mice with more advanced insulitis or 
are ineffective in clinical trials.  We were therefore particularly interested in examining the 
therapeutic potential of DC in late stages of disease in the NOD mouse. 
In this study we engineered syngeneic bone-marrow derived DC to overexpress soluble 
IL-4 (DC/sIL-4). In addition, exosomes were derived from DC/sIL4 and the abilities of these DC 
and DC-derived exosomes to prevent the onset of diabetes in 12-week old NOD mice were 
examined.  We demonstrate that these DC/sIL-4 induce changes in the balance of Th2 vs Th1 
effector profiles in splenocytes of treated mice, and induce upregulation of FoxP3 expression in 
the PLN of a subset of treated mice.  We further demonstrate that DC/sIL-4 prevent the onset of 
hyperglycemia when administered to 12-16 week-old NOD mice that demonstrate impaired 
response to glucose challenge consistent with prediabetes.  Lastly, we examined the exosomes 
secreted by the genetically engineered DC in order to determine if they could similarly regulate 
disease progression when systemically administered to 12-week old NOD mice, however our 
results indicate that DC-derived exosomes have little therapeutic effect in this model.  Taken 
together, our results indicate that DC/sIL-4 prevents islet destruction in late stages of type 1 
diabetes through modulation of T cell responses.   
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2.3 RESULTS AND DISCUSSION 
2.3.1 Characterization of DC transduced with IL-4-expressing vectors.   
We and others have previously shown that adenovirus transduction is an efficient means to 
transfer genes to DC, and that DC transduced to express IL-4 are therapeutic in preventing 
disease onset using mouse models of collagen-induced arthritis and delayed-type hypersensitivity 
[16, 167].  After transduction with an adenoviral vector expressing soluble murine IL-4 we 
observe significantly higher levels of IL-4 expression in the DC/sIL-4 than in the control or 
membrane IL-4 transduced DC culture conditions (Figure 1).  This is consistent with efficient 
gene transfer to DC using the adenoviral vector.   
We next examined the phenotype and maturation status of the DC by FACS in order to 
determine if infection with adenovirus resulted in significant differences in DC maturation.  Our 
culturing method results in a population of DC that is highly CD11c (>70%) and CD11b (>50%) 
positive (data not shown). We examined CD40 expression in all four populations, and find that 
~40% of DC were positive for CD40 regardless of whether they non-transduced or transduced 
with any one of the three vectors examined (data not shown).  As shown in Figure 2, we further 
observe that transduction with a control adenoviral vector (DC/ψ5) increases surface expression 
of B7-1, B7-2, and PD-L2, and decreases the expression of PD-L1.  DC/mbIL-4 demonstrated a 
similar pattern of changes in surface costimulatory molecule expression.  However, DC/sIL-4 
have decreased expression of B7-1 when compared to the DC/ψ5 or DC/mbIL-4, to levels more 
similar to those seen in the non-transduced DC.  Although transduced DC upregulate 
costimulatory molecules due to adenoviral infection, the high levels of IL-4 secreted by the 
DC/sIL-4 may have an autocrine regulatory effect on the balance of B7 molecules expressed by  
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Figure 1: DC Transduced with Ad.sIL-4 Secrete High Levels of IL-4 in Culture. 
After harvest on day 8, 1x106 DC were plated per well in OPTI-MEM media in a 96-well plate.  Following 24 
hours of culture, supernatants were analyzed by ELISA for levels of IL-4 secretion.  
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the DC.  This is consistent with previous findings whereby IL-4 regulates cytotoxic CD8+ T cell 
responses is by modulating the levels of B7-1 and B7-2 on DC [168]. 
2.3.2 DC expressing soluble IL-4 delay the onset of hyperglycemia in 12-week-old NOD 
mice.   
Female NOD/ShiLTJ mice were screened beginning at 11 weeks of age for the development of 
hyperglycemia. Most NOD mice will develop severe insulitis by 10 weeks of age, and in our 
experiments a small percentage (<10%) of mice will develop overt hyperglycemia by 12 weeks 
of age [157].  At 12 weeks, mice with blood glucose measurements <150 mg/dL were 
randomized to receive a single tail vein injection of 106 DC/sIL-4, 106 DC/mbIL-4, 106 DC/ψ5, 
or saline alone.  Blood glucose levels of mice were followed weekly and the percentage of mice 
developing hyperglycemia is shown in Figure 3.  Treatment with DC/sIL-4 conferred significant 
protection (p=0.05 using the log-rank test, p=0.02 using the Wilson rank test), as at 30 weeks of 
age only 50% of mice treated with DC/sIL-4 had developed diabetes as compared to >90% of 
saline-treated mice.  There was no therapeutic benefit seen in mice treated with DC/mbIL-4 or 
DC/ψ5, which were not statistically significant from mice treated with saline alone (p>0.05 for 
both groups using log-rank and Wilson rank tests). 
2.3.3 Evaluation of insulitis by histological analysis. 
12-week old normoglycemic mice received a single tail vein injection of 106 DC/sIL-4, 106 
DC/mbIL-4, 106 DC/ψ5, or saline alone and sacrificed at 15 weeks of age. Insulitis was 
evaluated by histology in order to determine the effect of treatment with DC/sIL-4 on  
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Figure 2: Characterization of DC Used for Adoptive Transfer. 
DC transduced with adenoviral vectors expressing soluble IL-4 (DC/sIL-4) or membrane-bound IL-4 
(DC/mbIL-4) or empty adenoviral vector (DC/ψ5) were compared to non-transduced DC (DC/Non). After 
harvest on day 8, 1x106 DC were plated per well in OPTI-MEM media a 96-well plate.  Following 24 hours of 
culture, supernatants were analyzed by by FACS.  Plots based on live DC as determined by FSC vs. SSC 
profiles.  Thin lines = isotype control stained samples, bold lines = anti-B7-1, -B7-2, -PD-L1, or -PD-L2 
antibodies, as shown.                                      
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mononuclear cell infiltration into the islets.  Three weeks following treatment, mice treated with 
DC/sIL-4 had sparsely infiltrated islets, with a majority of islets demonstrating no mononuclear 
cell infiltration or peri-insulitis (Figure 3A & B).  In contrast, mice treated with DC/ψ5 had 
infiltrative insulitis in slightly greater than half of the islets (Figure 3C & D).    Mice receiving 
saline alone had infiltrative insulitis in greater than 75% of all islets examined, with 50% of all 
islets completely infiltrated (Figure 3E &F).  The insulitis score (Figure 3G) at 15 weeks of age 
in DC/sIL-4 recipient mice was lower (1.45 ± 0.93) than in mice receiving DC/ψ5 (2.51 ± 0.95) 
or saline (3.19 ± 0.86) and there was a statistically significant difference between the insulitis 
scores of the DC/sIL-4 treated and saline treated animals (p=0.024).  The percentage of total 
intact islets and those with mild peri-insulitis in the DC/sIL-4 treatment group was 60%, which 
was twice the amount seen in the DC/ψ5 treated group (33.6%) and three times as many as that 
seen in the saline treated group (17.7%).  
2.3.4 DC/sIL-4 treatment increases IL-4 secretion by islet-antigen specific T cells. 
The balance of Th1 and Th2 cytokines plays an important role in the progression of autoimmune 
diseases, and in type 1 diabetes, a Th1-skewed balance of T cell responses contributed to the 
pathogenesis and progression of the disease [169-171].  Treatment with IL-4 has been shown to 
maintain Th2 CD4+ T cell responses that inhibit the progression of diabetes, and therefore we 
investigated whether DC/sIL-4 treatment had a beneficial effect on Th1/Th2 balance [159].  
Normoglycemic 12-week-old NOD mice were treated with 106 DC/sIL-4, 106 DC/mbIL-4, 106 
DC/ψ5, or saline alone, and at 15 weeks of age the frequency of splenic cells secreting IFN-γ or  
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Figure 3: Incidence of Diabetes Following i.v. Administration of DC Therapy to 12-week-old 
Normoglycemic Female NOD Mice.  
Mice were screened beginning at 11-weeks of age, and only mice with blood glucose measurements less than 
150 mg/dL were randomized to receive a single tail vein injection of either 1x106 DC/sIL-4, 1x106 DC/mbIL-4, 
1x106 DC/ψ5, or saline.  Combined results from 3 identical, independent experiments are shown.  * denotes 
significance of p≤0.05 by Wilcoxon’s test of DC/sIL-4 compared to DC/mbIl-4, DC/ψ5, and saline-treated 
groups.  The p-value of comparisons between the DC/mbIl-4, DC/ψ5, and saline-treated groups is greater 
than 0.05. 
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IL-4 in response was assessed by ELISPOT. Insulin, Gad65206-222, and NIT-1 cell lystate (a 
NOD-derived β-cell line) were used to stimulate islet-specific cytokine secretion in the 
splenocytes from treated mice.   As shown in Figure 5A, we did not see significant changes in 
the numbers of splenocytes secreting the Th1-accociated cytokine IFN-γ between treatment 
groups. In contrast, splenocytes from DC/sIL-4 treated mice exhibited a significant increase in 
the secretion of the Th2-associated cytokine IL-4 in response to all three antigens tested (Figure 
5B).  Therefore, we observed significant increases in the ratio of Th2/Th1 specific T cells after 
treatment with DC/sIL-4 in all three stimulation conditions, indicating that administration of 
DC/sIL-4 is able to induce changes in Th1/Th2 balance within NOD mice. 
2.3.5 DC/sIL-4 treatment upregulates FoxP3 expression in a subset of mice 
Three and four weeks following treatment with DC/sIL-4, mice were sacrificed and splenocytes 
analyzed by FACS to determine the proportion of CD4+ CD25+ FoxP3+ regulatory T cells 
within the spleen.  Cells were analyzed for the expression of FoxP3 and results are expressed as a 
ratio of CD4+ CD25+ FoxP3+ to the total number of CD4+ splenocytes.  As shown in figure 6A, 
our results indicate that DC/sIL-4 treatment did not have an effect on the levels of FoxP3+ 
regulatory T cells within the spleen. 
We next examined the relative changes in gene expression in the pancreatic lymph nodes 
of mice three weeks after treatment with DC/sIL-4 or controls.  The pancreatic lymph nodes 
(PLN) play an important role in the priming of inflammation in type I diabetes, and it has been 
demonstrated in numerous studies that adoptively transferred DC are capable of homing to both 
the spleen and PLN [144, 172].  In a recent studies comparing the gene expression profiles of 
NOD and NOD.B10 mice, it has been demonstrated that NOD mice loose PLN expression of IL-  
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Figure 4: Histological analysis of insulitis in mice following adoptive DC gene therapy.  
Normoglycemic mice received a single tail vein injection of either 1x106 DC/sIL-4, 1x106 DC/ψ5, or saline at 
12 weeks of age and were monitored until 15 weeks, when they were sacrificed.  Photomicrographs were 
taken of hematoxylin and eosin sections of pancreata collected from these mice.   Mice treated with DC/sIL-4 
show little or mild mononuclear infiltration surrounding the islets (A-B), whereas DC/ψ5 treated mice have 
moderate islet infiltration in the majority of islets (C-D), and the majority of mice treated with saline have 
severe insulitis (E-F).  (G) The insulitis score was determined by a blinded investigator using the following 
scale: 0=no lymphocytic infiltration; 1=peri-insultits; 2=insulitis affecting less than 33% of the islet area; 
3=insulitis affecting 33%-66% of the islet area; 4=insluitis affecting greater than 66% of the islet area. A 
minimum of 30 islets were evaluated per mouse on a minimum of 3 slides at least 100 mm apart.  Statistical 
comparison between the groups using Student’s t-test demonstrates: DC/sIL4 vs. Saline p=0.024, DC/sIL/4 vs. 
DC/ψ5 p=0.167, DC/ψ5 vs. Saline p=0.293. 
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Figure 5: Antigen-specific IL-4 secretion by splenic T cells following treatment with DC 
overexpressing IL-4. 
Normoglycemic mice received a single tail vein injection of either 1x106 DC/sIL-4, 1x106 DC/ψ5, or saline at 
12 weeks of age and were monitored until 15 weeks of age, when they were sacrificed.  Splenocytes were 
obtained from mice and assessed by ELISPOT for the frequency of splenic T cells secreting (A) IFN-γ, or (B) 
IL-4 in response to stimulation with GAD65206-220, insulin, and NIT-1 cell lysate. Results shown are 
representative of three mice per group.  Using student’s t-test, ** denotes significance at p<0.05 of DC/sIL-4 
treated group compared to both DC/ψ5 and saline treated groups, * denotes significance at p<0.05 of DC/sIL-
4 group compared to saline alone.   
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4 over time compared to their NOD.B10 counterparts [72], therefore we were interested in 
determining if treatment with DC/sIL-4 would result in corresponding changes in the levels of 
gene expression when compared to DC/ψ5 or saline treated animals.  We examined levels of IL-
4, IFN-γ, and FoxP3 expression in the PLN and inguinal lymph nodes (ILN) of treated mice by 
quantitative real-time PCR (qRT-PCR).  We examined the inguinal lymph nodes in order to 
ensure that baseline values of gene expression in the lymph nodes were not affected by DC-
based gene therapy, and indeed in all of the experiments, the levels of gene expression in the 
inguinal lymph nodes of mice was equivalent between groups. Our results indicate that there are 
no changes in levels of IL-4 or IFN-γ expression within the PLN of treated animals, but we did 
detect robust upregulation of FoxP3 in the PLN of half of the DC/sIL-4 treated mice (Figure  
6B).  This could be consistent with induction of a regulatory T cell phenotype, or recruitment of 
regulatory T cells into the local environment. 
2.3.6 A single administration of DC/sIL-4 prevents onset of hyperglycemia in prediabetic 
mice. 
Although many interventions prevent the onset of type 1 diabetes in animal models, few are 
effective when administered late in the disease process [173].  This is problematic, as the clinical 
reality of diabetes treatment is that patients present once they are experiencing symptoms, and at 
that point they typically have advanced disease.  Therefore, it is crucial to demonstrate that a 
therapy can be effective at preventing the onset of hyperglycemia when administered in the later 
stages of diabetes. 
 To this end, we monitored 12-16 week-old female NOD/ShiLTJ mice for the 
development of prediabetes, which we define as repeat random blood glucose measurement 
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between 150 mg/dL and 250 mg/dL.  As shown in Figure 7A, intraperitoneal glucose tolerance 
testing of 14-week-old mice identified as prediabetic using this criteria have a reduced response 
to glucose during challenge, with higher levels of blood glucose at all time points compared to 
mice in the normoglycemic group.  At 90 minutes, the blood glucose levels of the prediabetic 
group had still not returned to baseline, indicating an advanced state of insulitis and islet 
dysfunction.   
While DC/sIL-4 was capable of preventing disease in mice with advanced insulitis, we were 
interested to see whether this therapy was efficacious in this prediabetic population of NOD 
mice.  To this end, 12-16 week old mice prediabetic mice were randomized to receive a single 
tail vein injection of 106 DC/sIL-4, 106 DC/ψ5, or saline alone immediately after being classified 
as prediabetic.  Mice were monitored weekly for the onset of hyperglycemia, and the results are 
shown in Figure 7B.  DC/sIL-4 treatment significantly reduced the number of mice developing 
hyperglycemia compared to mice receiving DC/ψ5 or saline, indicating that even in more 
advanced stages of disease DC/sIL-4 can be an effective therapy to prevent the onset of type 1 
diabetes.   
2.3.7 Systemic administration of DC-derived exosomes does not delay the onset of 
hyperglycemia in 12-week-old NOD mice.   
We have previously demonstrated that exosomes secreted by DC transduced with IL-4 
are therapeutic in mouse models of delayed-type hypersensitivity and arthritis [16].  Despite a 
growing number of studies of exosome-based therapy for autoimmune disease, there have been 
no studies exploring the therapeutic potential of exosomes for type 1 diabetes to date.  Therefore, 
we were interested in testing whether systemic administration of DC-derived exosomes would  
 48 
 
 
 
 
 
Normoglycemic mice received a single tail vein injection of 1x106 of either DC/sIL-4 or DC/ψ5, or saline at 12 
weeks of age and were monitored until 15 or 16 weeks of age.  (A) Splenocytes were obtained from mice 3 and 
4 weeks post-treatment and analyzed by FACS for expansion of the CD4+CD25+FoxP3+ regulatory T cell 
compartment.   Splenocytes were stained using isotype control and monoclonal antibodies to CD4, CD25 and 
FoxP3.  Gates were set around live cells using FSC vs. SSC, then around CD4+ cells.  Isotype control staining 
was used to set the FoxP3 gating, and the number of CD4+CD25+FoxP3+ cells per sample were collected and 
are represented as a ratio of total CD4+ cells counted in each sample. (B) FoxP3 gene expression from 
pancreatic (PLN) and inguinal lymph nodes (ILN) obtained from mice at 15 weeks of age was analyzed using 
real-time PCR. Expression of FoxP3 was normalized to the expression of beta-actin to give the relative 
expression, and samples from all mice were then normalized to the mean of the saline-treated ILN group.   
 
 
 
Figure 6: Analysis of regulatory T cell induction by DC/sIL-4 treatment. 
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Figure 7: Incidence of diabetes following i.v. administration of DC therapy to 12-16 week-old 
prediabetic female NOD mice. 
Mice were screened beginning at 11-weeks of age, and mice with blood glucose measurements between 150 
and 250 mg/dL were considered prediabetic while mice with blood glucose measurements below 150 mg/dL 
were considered normoglycemic.  (A) Normoglycemic and prediabetic mice were injected with 2mg of L-
Dextrose per g of body weight, and their blood glucose measurements were measured at 15, 30, 60, and 90 
minutes post injection.  (B) Female prediabetic mice between 12 and 16 weeks of age were randomized to 
receive a single tail vein injection of either 1x106 DC/sIL-4, 1x106 DC/ψ5, or saline, and were then monitored 
for the development of hyperglycemia. * denotes significance of p≤0.05 by Wilcoxon’s test of DC/sIL-4 
compared to DC/ψ5, and saline-treated groups.  The p-value of comparisons between the DC/ψ5 and saline-
treated groups is greater than 0.05. 
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delay or prevent the onset of diabetes.  Exosomes were isolated from the enriched culture media 
of DC using differential centrifugation.  At 12 weeks, mice with blood glucose measurements 
less than 150 mg/dL were randomized to receive a single tail vein injection of 1 µg Exo/sIL-4, 1 
µg Exo/mbIL-4, 1 Exo/ψ5, or saline alone.  We have previously observed a dose of 1 µg to be 
effective at reducing disease when administered systemically by tail vein in collagen-induced 
arthritis and experimental autoimmune encephalomyelitis models.  As shown in Figure 8, 
systemic administration of DC-derived exosomes had no long-term protective effects. Although 
there may be some marginal early benefit observed in the Exo/mbIL-4 groups, this effect is not 
robust and by 30 weeks of age there are no statistically significant differences between the 
groups.     
2.4 CONCLUSIONS 
A large number of interventions are effective at preventing the onset of diabetes in young NOD 
mice. However, very few are effective at preventing the onset of hyperglycemia when 
administered after 10 weeks of age or when administered once disease onset has occurred [136, 
173]. Similar to previous results, we demonstrate the ability of IL-4 overexpressing DC to 
prevent diabetes onset in the NOD model [15, 72]. Our data indicate that DC/sIL-4 are capable 
of delaying disease onset (Figure 2) and reducing mononuclear infiltrate (Figure 3) in 
normoglycemic, but insulitic 12-week old mice. Our results are consistent with a recent report 
demonstrating that transduction of DC with a lentiviral vector expressing IL-4 prevents the onset 
of diabetes in 12-week old NOD mice [72]. However, we now have demonstrated that IL-4 
transduced DC can prevent the onset of hyperglycemia in prediabetic mice (Figure 6B).  
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Screening NOD mice for elevated blood glucose allowed us to efficiently select mice with 
impaired response to glucose challenge, which is indicative of more advance disease (Figure 6A) 
[174].  Interestingly, our results indicate that DC/sIL-4 are as or more effective at reversing 
disease onset in the prediabetic NOD mice (60% diabetes free at 32 weeks of age compared to 
14% of saline-treated mice) than 12-week-old normoglycemic mice (50% diabetes free at 32 
weeks of age compared to 14% of saline-treated mice).   Further, the therapeutic effect of the 
DC/sIL-4 is dependent upon their ability to secrete soluble IL-4, as we do not see any therapeutic 
benefit in mice receiving the DC/mbIL-4. 
Use of replication-deficient adenoviral gene vectors to deliver IL-4 to DC resulted in increased 
IL-4 expression by DC as well as an altered DC costimulatory molecule phenotype (Figure 1).  
Our data indicate that adenoviral infection results in upregulation of the costimulatory molecules 
B7-1, B7-2, and PD-L2, consistent with other studies evaluating adenoviral gene transfer to DC 
[61, 175].  We further observed that the high levels of IL-4 secreted into the culture media result 
in nearly identical expression levels of B7-1 on the DC/sIL-4 and non-transduced DC. This is 
consistent with a previous report indicating that IL-4 treatment of DC leads to upregulation of 
B7-2 and downregulation of B7-1, and that DC treated with recombinant IL-4 decrease in the 
activity of diabetogenic CD8+ cells in a manner dependent on B7-2 on the DC [168].  Although 
viral transduction induces changes in expression of DC costimulatory molecules, we hypothesize 
that overexpression of IL-4 mitigates some of these effects, and the resulting increased B7-2:B7-
1 ratio may contribute to the overall therapeutic effect of the DC/sIL-4 in vivo.  
Our analysis of the mechanism of the therapeutic effect of DC/sIL-4 demonstrated that DC/sIL-4 
administration to NOD mice results in increased islet-antigen specific secretion of the Th2-
cytokine IL-4, whereas there were no changes in the levels of secreted Th1 cytokine IFN-γ  
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Figure 8:  Incidence of diabetes following i.v. administration of DC-derived exosome therapy to 12-
week-old normoglycemic female NOD mice. 
Exosomes were isolated from the enriched media of DC cultures as described and resuspended in 500 µL of 
PBS at a dose of 1 µg.  Mice were screened beginning at 11-weeks of age, and only mice with blood glucose 
measurements less than 150 mg/dL were randomized to receive a single tail vein injection of either 1 µg 
Exo/sIL-4, 1 µg Exo/mbIL-4, 1 µg Exo/ψ5, or saline.  Combined results from 3 identical, independent 
experiments are shown. The p-value of comparisons between the Exo/sIL-4, Exo/mbIl-4, Exo/ψ5, and saline-
treated groups is greater than 0.05. 
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(Figure 4).  We hypothesize that this represents an alteration of the T cell responses within the 
treated animal, opposed to persistence of the DC/sIL-4 in vivo for several reasons.  First, 
ELISPOT assays were conducted three weeks following the administration of the DC/sIL-4.  
Previous studies using DC expressing firefly luciferase as a reporter gene indicate that DC 
selectively traffic to the spleen and pancreatic lymph node of NOD mice and expression of 
luciferase in these tissues suggests the numbers of DC peak in these tissues between day 1 and 
day 3 and then wane significantly by day 8 post-injection [72].  Secondly, the frequency of the 
observed IL-4 spot forming units in our assays significantly exceeds the original dose of 106 
DC/sIL-4 administered to the mice.  
 qRT-PCR analysis revealed that FoxP3 was significantly upregulated in the PLN of half 
of the mice receiving DC/sIL-4 (Figure 5B).  IL-4 has been shown to play a role in the 
extrathymic induction of FoxP3+ regulatory T cells [176].  In addition, we have previously 
shown that transduction of the islets with an AAV vector expressing IL-4 under the control of the 
mouse insulin promoter results in expansion of the percentage of CD4+CD25+FoxP3+ 
regulatory T cells as opposed to saline-treated control animals [160]. However, splenocytes of 
DC/sIL-4 treated mice showed no significant changes in the percentages of CD4+CD25+FoxP3+ 
T-cells when compared to control treated animals either three or four weeks following treatment 
(Figure 5A). Thus the induction of regulatory T cells in the PLN may predict which animals 
respond positively to DC/sIL-4 therapy.    
Lastly, we examined whether a single injection of 1 µg of exosomes derived from the 
supernatant of DC/sIL-4, DC/mbIL-4, or DC/ψ5 cultures would have any effect on the 
development of diabetes in normoglycemic 12-week-old NOD mice. However, in the NOD 
model, we did not see any remarkable therapeutic effects using a dose of 1 µg per mouse.  There 
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are a number of reasons why this may be the case.  While our previous results from the collagen-
induced arthritis model indicate that systemic injection of DC-derived exosomes are capable of 
modulating inflammation and reducing the severity of disease in that model, a single dose of 1µg 
may be insufficient and larger quantity of exosomes or repeat dosing may be necessary [16, 115, 
177, 178]. Furthermore, studies indicate that following i.v. injection, exosomes are internalized 
by splenic DC and hepatic kuppfer cells, which may be appropriate targets for some autoimmune 
diseases, such as arthritis, but not for others [104]. 
Collectively, our data demonstrate that adoptive transfer of DC/sIL-4 not only prevents 
the onset of diabetes in 12-week-old NOD, but can also maintain euglycemia in prediabetic mice 
ages 12-16 weeks of age that have demonstrated abnormalities in glucose homeostasis.  This is 
the first demonstration that DC/sIL-4 are capable of preventing disease onset at such a late stage 
of diabetes, and provides further confirmation that this approach is clinically relevant. A 
patient’s own DC could be harvested and transduced with adenovirus ex vivo, then administered 
via intravenous injection. As identification of patients at risk for type 1 diabetes improves, it may 
become increasingly possible to use a cell-based therapy such as DC/sIL-4 to prevent onset of 
disease in at risk individuals, or perhaps to intervene at the time of clinical diagnosis. 
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2.5 MATERIALS AND METHODS 
2.5.1 Mice.  
Female NOD/ShiLTJ mice were purchased from Jackson Laboratory (Bar Harbor, ME) and 
maintained in a specific pathogen-free facility at the University of Pittsburgh according to US 
Department of Agriculture and National Institutes of Health guidelines.  All experiments were 
conducted under protocols reviewed and approved by the Institutional Animal Care and Use 
Committee. 
2.5.2 Vector construction and Adenovirus Generation.  
Adenoviruses expressing soluble murine IL-4 (Ad.sIL-4) and membrane-bound (Ad.mbIL-4) and 
were constructed, propagated, and titered according to standard protocols as previously described 
[177].  The membrane-bound IL-4 construct is composed of IL-4 fused to the transmembrane 
domain of CD80. Recombinant adenoviruses were generated by homologous recombination in 
293 cells expressing Cre recombinase (CRE8 cells), after co-transfection with a plasmid  (ψ5) 
expressing the adenovirus 5-derived, E1- and E3-deleted adenoviral backbone and pAdlox, the 
adenoviral shuttle vector that expresses either sIL-4 or mbIL-4. Recombinant adenoviruses were 
purified by CsCl gradient ultracentrifugation, dialyzed in sterile virus storage buffer, aliquoted 
and stored at – 80oC.  
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2.5.3 DC Generation.  
BMDC were prepared following a bulk-culture protocol modified from Son, et al. as previously 
described [179, 180]. Briefly, bone marrow was collected from tibias and femurs of 6- to 7-
week-old female NOD/ShiLTJ mice.  Contaminating erythrocytes were lysed with ACK cell 
lysing buffer (Mediatech, Herdon, VA).  Monocytes were collected from the interface after 
centrifuging on Nycoprep (NycoMed, Roskilde, Denmark) at 600 x g for 20 min at RT.  Cells 
were cultured for 24 h in complete media (RPMI 1640 containing 10% FBS, 50 µM 2-β-
Mercaptoethanol, 2 mM glutamine, 0.1 mM nonessential amino acids, 100 IU/mL 
penicillin/streptomycin) to remove adherent macrophages.  Non-adherent cells were placed in 
fresh growth media (complete media containing 1000 U/mL of GM-CSF and IL-4) to generate 
DC.  Cells were cultured for 4 days then harvested for adenoviral (Ad) transduction. For Ad 
infection, 1 X 106 DC were incubated with 5 X 107 PFU of the virus in 1mL of serum-free media 
for 2 hours, and then 10 mL complete media was added to the cells.  After overnight incubation, 
DC were washed vigorously three times in PBS to remove excess virus and cultured for an 
additional 48 h in growth media.  On day 8, culture supernatant was collected for exosome 
purification and DC were recovered. This infection method routinely gives us ~70-80% 
transfection efficiency using Ad.eGFP as a control [181]. 
2.5.4 FACS Analysis of DC.  
Dendritic cells were preincubated with anti-CD16/32 (eBioscience, San Diego, CA), then stained 
with 1-2 µL of PE-labeled mAbs (B7.1 (16-10A1), B7.2 (PO3.1), PD-L1 (MIH5), PD-L2 
(TY25), CD40 (1C10), CD11b (M1/70), and CD11c (N418), all from eBioscience, San Diego, 
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CA) in 100 µL total volume of ice-cold PBS containing goat serum. Following staining, cells 
were washed twice in FACS buffer, resuspended in 400 µL FACS buffer, and examined by 
FACS (FACScan, BD Biosciences, San Jose, CA).  Results were analyzed using FlowJo 
(Treestar Inc. Ashland, OR). 
2.5.5 ELISA Analysis of DC Supernatant.   
Supernatants from DC were collected and analyzed using a sandwich ELISA to detect IL-4 
(eBioscience San Diego, CA) according to the manufacturer’s protocol.  The limits of detection 
were 4 pg/mL. 
2.5.6 Exosome Isolation.  
Exosome isolation procedure has previously been described [115].  Briefly, DC culture 
supernatants were collected and centrifuged at 300 g for 10 min, 1200 g for 20 min, and 10,000 g 
for 30 min, and then ultra-centrifuged at 100,000 g for 1 h.  Exosome pellet was washed in sterile 
PBS, centrifuged at 100,000 g for 1 h, and resuspended in 120 ml of PBS for further studies. 
Exosome batch protein content was quantified and standardized by a micro Bradford protein 
assay (Bio-Rad, Hercules, CA). 1 mg exosomes were suspended in 20 ml of PBS for in vivo 
mouse studies. 
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2.5.7 Adoptive Transfer of DC and Exosomes to NOD/ShiLTJ mice.   
Blood glucose levels of NOD/ShiLTJ mice were monitored using blood drawn from the tail vein 
and analyzed via a glucometer (Ascencia BREEZE; Bayer).  Mice with blood glucose readings 
below 150 mg/dL were considered normoglycemic.  Mice with repeat measures between 150 and 
250 mg/dL on consecutive days were considered prediabetic, and mice with repeat measures 
greater than 300 mg/dL on consecutive days were considered hyperglycemic. 
To test the ability of treatment to delay diabetes onset, normoglycemic 12-week old 
female NOD/ShiLTJ mice were randomized to received a single tail vein injection containing 
one of the following:  106 DC therapy, 1 µg exosomes therapy, or PBS alone.  For studies 
examining the ability of DC therapy to prevent diabetes in prediabetic mice, mice 12-16 weeks 
of age and with repeat blood glucose measurements between 150 and 250 mg/dL were 
randomized to received a single tail vein injection containing either 106 DC therapy, or PBS 
alone.  
2.5.8 Intraperitoneal Glucose Tolerence Test.  
Mice were fasted for 12 hours, and then weighed.  Baseline blood glucose measurement was 
determined prior to i.p. injection with L-Dextrose (Sigma-Aldrich, St. Loius, MO) suspended in 
PBS at a dose of 2 mg per gram of body weight.  Repeat blood glucose measurements were 
determined at 15, 30, 60, and 90 minutes following dextrose injection.  
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2.5.9 Histology and Islet Grading.  
Pancreata were collected from 15-week old mice following DC therapy at 12 weeks of age, and 
were fixed, and embedded.  5 mm sections were deparaffinized, stained with hematoxylin and 
eosin, and evaluated by a blinded investigator for infiltrating mononuclear cells within the islets.  
Individual islets were assigned scores based on their appearance: 0=no lymphocytic infiltration; 
1=peri-insultits; 2=insulitis affecting less than 33% of the islet area; 3=insulitis affecting 33%-
66% of the islet area; 4=insluitis affecting greater than 66% of the islet area.  The histology score 
index per mouse was calculated by dividing the sum of all individual islets scored by the total 
number of islets evaluated, and was used to represent each mouse in statistical testing.  A 
minimum of 30 islets were evaluated per mouse on a minimum of 3 slides at least 100 mm apart. 
2.5.10 Evaluation of splenic antigen-specific responses by ELISPOT and splenic regulatory 
T cell levels.  
15-week old mice were sacrificed following DC therapy at 12 weeks of age.  Spleens were 
collected and splenocytes immediately extracted.  Contaminiating erythrocytes were lysed with 
ACK lysis buffer (Mediatech, Herdon, VA). 
For ELISPOT assay, 5x105 splenocytes per well were stimulated with GAD65206-220 (50 
ug/mL, Anaspec, Freemont, CA), insulin (50 ug/mL Sigma-Aldrich, St. Loius, MO), NIT-1 
freeze-thaw cell lysate (20 ug/mL), or OVA protein (50 ug/mL Sigma-Aldrich, St. Loius, MO) in 
serum-free media in 96-well ELISPOT plates precoated with an anti-IL-4 or anti-IFN-γ mAbs. 
ELISPOT plates were cultured for 36 hours followed by incubation with biotin conjugated-anti-
IL4 or anti-IFN-γ mAb, and development with streptavidin-peroxidase and 3-amino-9-
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ethylcarbazole according to manufacturer’s recommendations (BD Biosciences, San Jose, CA).  
Spots were counted with an ImmunoSpot counter (Cellular Technology, Shaker Heights, OH).  
Stimulations were conducted in triplicate per mouse per antigen. 
To evaluate levels of splenic T regulatory cells, splenocytes were surface stained with 
antibodies for CD4 (clone RM4-5) and CD25 (clone PC61.5), for 30 minutes at 4°C according to 
the manufacturer’s recommendations (eBioscience, San Diego, CA).  Cells were washed then 
incubated in the dark at 4°C in fixation/permeabilization buffer overnight.  Cells were again 
washed and resuspended in permeabilization buffer, and incubated in the dark at 4°C for 1 hr 
with an anti-FoxP3 monoclonal antibody (clone FJK-16s, eBioscience).  Cells were washed 
twice with permeabilization buffer, then resuspended with FACS buffer and examined by FACS 
(FACScan, BD Biosciences).   
2.5.11 Quantitative PCR.  
15-week old mice were sacrificed following DC therapy at 12 weeks of age.  Pancreatic lymph 
nodes (PLN) were harvested and RNA isolated according to manufacturer’s recommendations 
using an RNAqueous-Micro Isolation Kit (Ambion, Austin TX). 375 ng RNA was used as a 
template to generate cDNA using SuperScript III First-Strand Synthesis Kit for qRT-PCR 
(Invitrogen, Carlsbad, CA).  Real-time PCR was done using SYBR GreenER qPCR SuperMix 
(Invitrogen) kit on an iQ5 device (Biorad, Hercules, CA). The SuperMix kit uses Fluorescein to 
normalize the fluorescence fluctuations between reactions.  Primers used for qRT-PCR were: 
GACGGCCAGGTCATCACTAT (ß-actin forward), AAGGAAGGCTGGAAAAGAGC (ß-actin 
reverse), TCTTGCCAAGCTGGAAGACT (FoxP3 forward), GGGGTTCAAGGAAGAAGAGG 
(FoxP3 reverse). 
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2.5.12 Statistics. 
Survival analysis was conducted using Kaplan-Meier analysis and a Wilcoxon’s test for 
significance between groups on Stata statistical software (College Station, TX). Other results 
were compared by Student’s t test or ANOVA with Fisher’s Least Significant Difference post-
hoc test using SPSS statistical software (Chicago, IL).   P values ≤ 0.05 were considered 
statistically significant. 
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3.0  THERAPEUTIC ROLES OF INDOLEAMINE-2,3-DIOXYGENASE AND B7 
FAMILY MEMBERS IN TOLEROGENIC DC AND EXOSOMES 
3.1 ABSTRACT 
We have demonstrated previously that dendritic cells (DC), modified with immunosuppressive 
cytokines, as well as exosomes derived from these DC can reduce inflammation in murine 
collagen induced arthritis (CIA) and delayed-type hypersensitivity (DTH) models.  Although we 
have previously shown that these effects are dependent on MHC II and FasL, much work 
remains to be done to understand the mechanism underlying the ability of tolerogenic DC and 
the exosomes they secrete to confer suppression in vivo.  Herein we examine the roles of 
Indoleamine 2,3-dioxygenase (IDO) and the T cell costimulatory molecules B7-1, B7-2, PD-L1 
and PD-L2 on the surface of tolerogenic DC and exosomes, as these have been demonstrated to 
be two key mechanisms involved in DC-mediated tolerance. In this study, we first examine the 
immunosuppressive effects of bone marrow derived DC and DC exosomes, genetically modified 
to express IDO. Bone marrow derived DC were adenovirally transduced with IDO or CTLA4-Ig 
(an inducer of IDO), and the resulting DC and exosomes were tested for their 
immunosuppressive ability in the DTH model. We demonstrate that both DC and exosomes 
derived from DC overexpressing IDO are anti-inflammatory the DTH model, and that the 
suppressive effects of exosomes from IDO-overexpressing DC were partially dependent on B7 
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costimulatory molecules.  In order to determine the role of B7 family members in tolerogenic DC 
and exosomes in general, we examined the contributions of B7-1/2 and PD-L1/2 to the function 
of IL-10-treated, immunosuppressive DC as well as therapeutic exosomes derived from these 
DC. We demonstrate that absence of B7-1 or B7-2 on donor DC results in a loss of ability of IL-
10 treated DC and their exosomes to suppress the delayed-type hypersensitivity (DTH) response, 
whereas IL-10 treated DC deficient in PD-L1/2 as well as their secreted exosomes retained the 
ability to suppress DTH responses. These results demonstrate that both IDO expressing DC and 
DC-derived exosomes are immunosuppressive and anti-inflammatory, and may represent a novel 
therapy for autoimmune disease. We further conclude that B7-1 and B7-2, but not PD-L1 and 
PD-L2, on DC and DC-derived exosomes play a critical role in immunosuppressive functions of 
both DC and exosomes.   
3.2 INTRODUCTION 
Dendritic cells (DC) are professional APC which play a crucial role in mediating the balance 
between immunity and tolerance in vivo, and therefore have been increasingly studied for 
therapeutic applications in allergy, infection, and autoimmunity.  Significant efforts in the field 
of autoimmunity have been made to understand the genesis and function of DC that are 
immunosuppressive rather than stimulatory, and to understand their underlying phenotype [182].   
Previously, we have demonstrated several effective modifications of dendritic cells (DC) which 
confer suppressive abilities to DC in vivo in delayed-type hypersensitivity (DTH) and collagen-
induced arthritis (CIA) models.  These include adenoviral gene transfer of IL-4 and FasL to DC, 
as well as rIL-10 treatment of DC [16, 67, 115, 177].  Furthermore, these studies demonstrated 
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that exosomes produced by modified DC could also be used to suppress inflammation in vivo in 
the DTH and CIA models.  The exosomes secreted by the modified DC have been equally 
effective as the DC at decreasing disease.  However, these exosomes are likely a better 
therapeutic avenue compared to DC, as exosomes are believed to be of a stable phenotype once 
secreted, while DC may undergo phenotype switching towards pro-inflammatory phenotype and 
thus worsen rather than mitigate disease. 
Exosomes are small (40-100nm) membrane vesicles that originate in the multivesicular 
endosome of many cell types.  Exosomes derived from APC, in particular DC, have the potential 
to promote immunity or tolerance in disease models of cancer, transplant or autoimmunity [183].  
Exosomes carry molecules important for antigen presentation, also found on DC, such as major 
histocompatibility complex (MHC) class I and II, and B7 family costimulatory molecules such as 
B7-1, B7-2, and PD-L1, which allow them to regulate antigen specific immune responses [92, 
96].  Exosomes are capable of interacting directly with T cells [184, 185], but also can act as a 
potential source of antigen or MHC complexes for APC presentation [186, 187].  Our previous 
studies demonstrated that in vivo mechanism of action of suppressive exosomes relies on MHC II 
and FasL, but not MHC I, while others have shown that B7-1 is important for exosome function 
in vitro [19, 20].  However, the mechanisms by which exosomes mediate their effects on host 
cells in vivo remains largely unclear at this time. 
Indoleamine-2,3-Dioxygenase (IDO) is a tryptophan-catabolizing enzyme that catalyzes 
the rate-limiting first step in the degradation of tryptophan to a series of products, termed L-
kynurenines.  IDO plays a critical role in the maternal tolerance of the fetus [188], and has been 
demonstrated to be of importance in maintenance of tolerance in numerous settings including: 
cancer, rheumatoid arthritis, and transplantation [189-191].  IDO exists in two forms, IDO-1 and 
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IDO-2, and studies have shown that although both are expressed in DC, only IDO-1 mediates 
tryptophan conversion in DC [192]. IDO is upregulated in DC following several different 
stimuli, including IFN-γ, IFN-α, TNF-α, glucocorticoid-induced tumor-necrosis factor receptor 
(GITR), CD40L, and importantly, through reverse signaling following binding between B7 
molecules on DC and CD28/CTLA-4 on CD4+ helper T cells [29, 193].  The exact mechanisms 
by which IDO confers tolerance are complex and as yet not fully elicited; however, two theories 
have been proposed.  First, depletion of the essential amino acid tryptophan may reduce effector 
T cell proliferation by limiting the availability of this essential nutrient.  It has been demonstrated 
that T cells can sense IDO-mediated depletion of tryptophan via GCN2 kinase, resulting in T cell 
anergy [194].  Other studies suggest that IDO does not function through depletion of tryptophan 
alone, and suggest that kynurines may be capable of conferring IDO-mediated signals from cell 
to cell [195].  However, both mechanisms may play important roles in conferring the tolerogenic 
effects of IDO. 
As stated one of the mechanisms of IDO activation is via activation of costimulatory 
molecules.  These signaling molecules play a critical role in determining immune system 
specificity and self-tolerance.  The best characterized costimulatory molecules are B7-1 (CD80) 
and B7-2 (CD86), which are primarily expressed on APC and can either stimulate or antagonize 
T cell function via interaction with CD28 or CTLA-4 respectively [196].  B7-1 and B7-2 
expression on APC is critical for homeostatic balance in not only effector T cell populations, but 
also in DC and regulatory T cell populations as well.  CTLA-4 ligation of B7 signals 
bidirectionally, sending signals both into the T cell and inducing DC expression of IDO, which 
inhibits T cell function [197].  Novel members of the B7 family are also integral in controlling 
the DC and T-cell responses.  Programmed Death-1 (PD-1)  is expressed on activated T-cells 
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while its ligands PD-L1 and PD-L2 are expressed on numerous cell types including DC.  The 
PD-1:PD-L1/2 signaling pathway plays an important negative regulatory role in T cell function 
and regulates peripheral T cell tolerance at multiple checkpoints [198].  Programmed Death-1 
(PD-1) is upregulated on T cells upon activation, and its ligands, Programmed Death 1-Ligand 1 
(PD-L1, also known as B7-H1) and Programmed Death 1-Ligand 2 (PD-L2, also known as B7-
H2), have distinct expression patterns, with PD-L1 being expressed much more broadly than PD-
L2.  Both PD-L1 and PD-L2 are expressed on DC. Of significant interest, recent work indicates 
that PD-L1 and PD-L2 may not only regulate T cell responses by engaging PD-1 and modify 
TCR signaling, but also may act via reverse signaling and deliver signals into the PD-L1 and PD-
L2-expressing cells.  Treatment of DC with soluble PD-1Ig, inhibited their activation, resulted in 
increased IL-10 production, leading to a suppressive DC phenotype, which was independent of 
IDO upregulation. These effects could be prevented by neutralization of PD-1Ig with anti-PD-1, 
indicating that this phenotype is PD-1 specific and implicating PD-L1 or PD-L2 binding [199].  
Because of their demonstrated abilities to confer suppressive properties to DC, we were 
particularly interested in examining the roles of B7-1/2 and PD-L1/2 costimulatory molecules in 
the context of immunosuppressive DC therapy.   
Due to the immunosuppressive activity of IDO+ DC, I have examined whether exosomes 
derived from IDO-expressing DC would be therapeutic in blocking inflammation in a footpad 
DTH model of antigen-specific inflammation.  Herein, I document that exosomes derived from 
IDO+ DC are anti-inflammatory and therapeutic in the DTH model.  In addition, I demonstrate 
that exosomes from CTLA4-Ig expressing DC reduced inflammation in an manner dependent on 
IDO in transduced DC, IDO dependent manner, suggesting that IDO either exogenously 
expressed or induced endogenously in recipient DC results in a suppressive phenotype.  
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Moreover, these results demonstrate that IDO expression in DC results in the generation of 
immunosuppressive exosomes.   
In addition to DC derived exosomes altering the phenotype of host DC, there is data 
suggesting that DC derived exosome may interact and alter T-cell function within the host.  
Previous data by Kim et al. implicated MHC II and FasL, but not MHC I in the in vivo 
suppressive qualities of exosomes [19, 115].  Further data implicating a role for B7 signaling in 
the induction of IDO drew our interest to the role of B7 molecules and exosomes [19, 115].  
Many of the factors important for exosome suppressive qualities including B7, MHC II and FasL 
are T-cell ligands [19, 20].  Thus, we hypothesized that direct interaction of exosomes with T-
cells may play an important role in immune regulation of inflammation in the DTH model.  In 
addition, the B7 family of costimulatory molecules may be required for these in vivo suppressive 
effects.  Herein we demonstrate that the suppressive effects of exosomes derived from IDO+ DC 
in the DTH model were partially dependent on B7-1 and B7-2 costimulatory molecules, as 
exosomes from B7-1 and B7-2 knockout mice had reduced ability to confer the therapeutic 
effect.  We further demonstrate that B7-1 and B7-2 are necessary for the in vivo suppressive 
function of both IL-10 treated DC and their secreted exosomes in the DTH model. This indicated 
that regardless of the method used to generate suppressive exosomes, B7-1 and B7-2 play a 
significant role in conferring their therapeutic effects. In contrast, we show that PD-L1 and PD-
L2 on DC and DC-derived exosomes are not necessary for their immunosuppressive activity in 
the DTH model. 
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3.3 RESULTS AND DISCUSSION 
3.3.1 Inhibition of inflammation in the DTH model by local administration of DC 
genetically modified to overexpress IDO and exosomes from IDO+ DC 
It has been previously demonstrated that upregulated levels of IDO in DC in vivo are associated 
with tolerance in models of transplantation, cancer and autoimmunity [29].  Therefore, we were 
interested in methods to generate IDO+ tolerogenic DC ex vivo.  In Bianco et al, we show that 
adenoviral transduction of DC with an IDO vector results in DC which are capable of 
ameliorating disease in the CIA model of rheumatoid arthritis [68]. CTLA-4-Ig is a synthetic 
fusion protein that binds with high affinity to B7-1 and B7-2, resulting in the upregulation of 
IDO [29].  To determine the effect of CTLA-4-Ig and IDO transduction on DC, DC were 
infected with IDO and CTLA-4-Ig expressing vectors and then cultured in vitro for an additional 
3 days prior to the harvesting of DC or derivation of exosomes from the enriched supernatant.  
Our results indicate that transfection of DC with either IDO or  CTLA-4-Ig expressing vector is 
an effective means to generate IDO+ DC ex vivo, as western blotting confirmed that CTLA-4-Ig 
transfected DC upregulated IDO compared to non-treated control DC (Figure 9A). We have 
previously demonstrated that the exosomes derived from the CTLA-4-Ig expressing DC are 
therapeutic in the CIA model [68].  We have further demonstrated that IDO overexpression in 
DC via transfection with IDO or CTLA-4-Ig adenoviral vectors results in slight, but detectable 
levels of IDO in the exosomes, whereas no IDO can be detected in control exosomes (Figure 
9B).  FACS analysis demonstrated there were no significant differences between the transduced 
and non-transdueced DC used in this study (Table 4).   
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(A) DC extracts (2 µg) from non-infected Ad.CTLA4-Ig cells were run on a 12% SDS-PAGE gel and 
immunoblotted for IDO or β-actin. Numbers indicate relative semi-quantitative expression of IDO after 
normalization to β-actin using the NIH software program Image J.  (B) Exosomes were isolated from bone 
marrow derived DC that were previously infected with Ad.CTLA4-Ig and treated with ±1-MT or L-Trp, or 
non-infected. Five µg of total exosome protein was run on a 15% SDS-PAGE gel and immunoblotted for IDO, 
CTLA4-Ig, or β-actin.  
Reprinted with permission from: Bianco NR, Kim SH, Ruffner MA, Robbins PD. “Therapeutic Effect of 
IDO+ DC in CIA and DTH disease models.” Arthritis & Rheumatism 2009. 60(2) 380-9. 
 
 
 
Figure 9: Transduction with IDO or CTLA-4-Ig vectors 
results in expression of IDO in DC and DC-derived exosomes. 
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Figure 10: Suppression of DTH by IDO+ DC and DC-derived exosomes. 
Exosomes were isolated from BM-DC that were either infected with the Ad.Ψ5 (control) or Ad.IDO.  The 
purified DC or exosomes were injected into the right footpad of KLH-immunized C57 BL/6 mice 
concurrently as KLH was injected into both hind footpads and the extent of swelling was measured at 48 h. 
Dark bars represent difference of footpad thickness in the treated paws and white bars in the non-treated 
contra-lateral paws (n=5). * denotes significance of P≤0.0 01 compared to DC/Psi5, Exo/Psi5, and Saline 
controls for both treated and contralateral paws. 
Reprinted with permission from: Bianco NR, Kim SH, Ruffner MA, Robbins PD. “Therapeutic Effect of 
IDO+ DC in CIA and DTH disease models.” Arthritis & Rheumatism 2009. 60(2) 380-9. 
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Table 4: FACS analysis of DC used in this study* 
 
* DC were stained with PE-conjugated monoclonal antibodies against murine surface molecules (CD80, 
CD86, H-2Kb, I-Ab, and appropriate isotype controls). Isotype-matched irrelevant mAbs were used as 
negative controls (control=1.12%). 
Reprinted with permission from: Bianco NR, Kim SH, Ruffner MA, Robbins PD. “Therapeutic Effect of 
IDO+ DC in CIA and DTH disease models.” Arthritis & Rheumatism 2009. 60(2) 380-9. 
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To determine if exosomes from DC genetically-modified to express IDO were therapeutic in a 
model of antigen-specific inflammation, a mouse model of DTH was used.  To induce a Th1-
driven DTH response, mouse were immunized to keyhole limpet hemocyanin (KLH) in complete 
freund’s adjuvant at a single dorsal site two weeks prior to the introduction of antigen in the hind 
footpads.  Either 106 or 1 µg of exosomes were concomitantly injected into the right hind footpad 
with the KLH antigen at the time of secondary antigen challenge in order to assess the ability of 
the DC or DC-derived exosomes to modulate the inflammatory response.  Local injection of DC 
transfected with an IDO adenoviral vector (DC/IDO) significantly reduced paw swelling in both 
the treated and contralateral paw (Figure 10).  Exosomes derived from the DC/IDO (Exo/IDO) 
were equally effective as the parental DC at reducing paw swelling in the treated as well as 
contralateral paws in the DTH model (Figure 10).   
These results suggest that both DC/IDO  and Exo/IDO are effective at suppressing 
inflammation at local as well as distant sites of inflammation.  DC and DC-derived exosomes 
injected into the hind footpads of mice traffic to the ipsilateral draining popliteal lymph node, 
where they have been shown to interact with CD11c+ DC and F480+ macrophages [16, 67].  
However, the mechanism whereby exosomes modulate inflammation in vivo both locally and at 
distant sites remains unclear. 
We have further demonstrated that DC transfeted with CTLA-4-Ig (DC/CTLA-4-Ig) 
suppress paw swelling in the DTH model (Figure 11A).  Exosomes derived from these DC 
(Exo/CTLA-4-Ig) are also capable of ameliorating inflammation in the treated and contralateral 
paws at levels comparable to the parental DC (Figure 11A).  The addition of 1-MT, an inhibitor 
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of IDO, but not excess L-tryptophan, to the DC cultures resulted in inhibition of the anti-
inflammatory effect of CTLA-4-Ig (Figure 11B).  As seen in Figure 11B, exosomes derived from 
1-MT treated DC/CTLA-4-Ig are not capable of suppressing paw swelling.   This is consistent 
with the known ability of CTLA-4-Ig to generate a suppressive DC phenotype by upregulation of 
IDO, and our results indicating that upregulation of IDO does indeed occur in the DC/CTLA-4-
Ig.  Furthermore, this suggests that expression of IDO and not CTLA-4-Ig is critical for the in 
vivo suppressive effects seen in Exo/CTLA-4-Ig Altogether, these results support the conclusion 
that exogenous induction of IDO over-expression in DC results in a suppressive DC population, 
and that these DC as well as the exosomes they secrete can be used therapeutically in the DTH 
model. 
3.3.2 Cells expressing IDO produce L-kynurenines, which can be detected in culture 
supernatants, but not in exosomes 
IDO is the rate-limiting first enzymatic step in the catabolism of tryptophan to degradation 
products termed kynurenines.  Belladonna et al. have demonstrated that in the presence of IFN-γ,  
kynurenines are capable of inducing tolerogenic properties in CD8- DC, demonstrating that the 
paracrine production of kynurenines is an important cell-cell signaling mechanism [195].  To 
determine whether it is plausible that exosomes from IDO-overexpressing DC could confer their 
suppressive effect by delivery of kynurenines to target cells in vivo, we performed an assay for 
the levels of L-kynurenine in purified exosomes and exosome-free supernatant.  For this 
experiment, we used TA3 Hauschka cells (TA3 cells), a mouse mammary carcinoma line, due to 
their relative ease of adenoviral transduction and ability to produce large quantities of exosomes.  
The TA3 cells were infected with Ad.IDO, Ad.eGFP as a control, or left uninfected.  As shown  
 74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: CTLA4-Ig+ DC and Exo suppress DTH in an IDO-dependent manner. 
Exosomes were isolated from BM-DC that were infected with Ad.CTLA4-Ig and treated with ± 1-MT or L-
trp.  Purified DC or exosomes were injected into the right footpad of KLH-immunized C57 BL/6 mice 
concurrently as KLH was injected into both hind footpads and the extent of swelling was measured at 24 h 
(B) or 48 h (A). Note that (B) is exosomes only. Dark bars represent difference of footpad thickness in the 
treated paws and white bars in the non-treated contra-lateral paws (n=5). (A)* denotes significance of 
P≤0.001 compared to DC/eGFP, Exo/eGFP, and Saline Control Groups for both treated and contralateral 
paws (B) * denotes significance of P≤0.05 of CTLA4-Ig compared to controls Psi5, CTLA4-Ig+1MT and 
Noninfected controls for the treated paws, as well as significance of P≤0.05 of IDO group compared to all 
groups excepting the CTLA-4-Ig and CTLA-4Ig+1MT for both treated and contralateral paws.  
Reprinted with permission from: Bianco NR, Kim SH, Ruffner MA, Robbins PD. “Therapeutic Effect of 
IDO+ DC in CIA and DTH disease models.” Arthritis & Rheumatism 2009. 60(2) 380-9. 
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in Figure 12, we observe high levels of L-kynurenine production only in the exosome-free 
supernatant of the Ad.IDO infected cells as compared to the control groups.  We do not detect L-
kynurenine in any of the exosome groups.  It therefore seems unlikely that delivery of 
kynurenines to target cells is a main mechanism by which exosomes form IDO-overexpressing 
cells confer their effects. 
3.3.3 Anti-inflammatory effect of exosomes from DC/IDO are dependent on B7-1 and B7-
2 for their mechanism of action 
As shown in Figure 9, Exo/IDO also contain IDO, and delivery of IDO to target cells may be one 
mechanism by which they confer suppression in vivo. However, we were also interested in 
quality is not a consequence of differing levels of IDO between groups but that the 
immunosuppressive function of exosomes derived from IDO-overexpressing DC depend on B7-1 
and B7-2 on the exosomes surface.   
Given that B7-1 and B7-2 on the DC surface are known to have intracellular signaling 
capability which upregulate IDO [29], it is unclear whether or not the requirement for B7 
molecules on the surface of tolerogenic exosomes is related in some way to the fact that they 
were generated form IDO-overexpressing DC. Therefore, in the following experiments, we set 
out to determine if the requirement for B7-1 and B7-2 for in vivo efficacy of BMDC and DC-
derived exosomes was related to the specific adenoviral therapies used in these previous studies, 
or represented a more general phenomenon that could be generalized to other populations of 
suppressive DC and exosomes. 
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Figure 12: Exosomes from IDO+ cells do not contain trp metabolites. 
TA3 cells were either non infected (non) or infected with rAd containing expression cassettes for either eGFP 
or IDO.  Exosomes were collected from the culture supernatant, and verification of IDO expression was 
conducted by western blot (data not shown. Exosomes (1 µg) or exosome-free supernatants (60µl) were 
assayed for levels of L-kynurenine. 
Reprinted with permission from: Bianco NR, Kim SH, Ruffner MA, Robbins PD. “Therapeutic Effect of 
IDO+ DC in CIA and DTH disease models.” Arthritis & Rheumatism 2009. 60(2) 380-9. 
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Figure 13: DTH suppression by exosomes is dependent on B7-1 and B7-2. 
BM-DC from wild type C57BL/6 mice or B7-1KO, B7-2KO, or double knockout (DKO) were transduced with 
Ad.IDO or non-infected. (A) Exosomes were isolated from the DC media. Purified exosomes were injected 
into the right footpad of wild-type KLH-immunized mice concurrently with injection of KLH antigen into 
both hind footpads, and the extent of swelling was measured at 24 h. Dark bars represent difference of 
footpad thickness in the treated paws and white bars in the non-treated contra-lateral paws (n=5). * denotes 
significance of P≤0.05 compared to all other groups for both treated and contralateral paws. (B) Five µg of 
total DC or exosome protein extract was run on a 15% SDS-PAGE gel and immunoblotted for IDO or β-
actin. 
Reprinted with permission from: Bianco NR, Kim SH, Ruffner MA, Robbins PD. “Therapeutic Effect of 
IDO+ DC in CIA and DTH disease models.” Arthritis & Rheumatism 2009. 60(2) 380-9. 
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3.3.4 IL-10 treatment of BMDC results in tolerogenic phenotype   
The levels of the B7-1/2 and PD-L1/2 costimulatory molecules on DC before and after 24 hours 
of treatment with IL-10 were examined. As shown in figure 1A, IL-10 treatment of BMDC 
resulted in highly decreased levels of MHC I (H-2kb), B7-1, B7-2, as well as lowered levels of 
MHC II (IA/IE) and PD-L2 after 48 hours.  Similarly, Western blotting demonstrated that IL-10 
treated DC have decreased overall expression levels of B7-1 and B7-2 (Figure 1B), in addition to 
decreased surface expression.  These observations are consistent with published reports 
regarding the ability of IL-10 treatment to downregulate levels of costimulatory molecules on 
DC [15, 16], thereby generating a tolerogenic DC phenotype.  We also examined the secreted 
levels of the proinflammatory cytokines IL-6, IL-23(p19/p40), IL-12p70, and IL-12/IL-23 total 
p40 by ELISA from supernatants of IL-10 and non-treated DC, plus/minus 24 hours of 
stimulation with 100ng/mL of LPS.  We found that DC treated with IL-10 do not have increased 
IL-12 or IL-23 production when stimulated with LPS.  In addition, although the LPS-stimulated 
DC.IL10 produce an increased amount of IL-6, it was significantly less than the amount 
produced by the non-treated control DC in response to LPS stimulation (Figure 1C).  
Collectively, these results confirm that an immunosuppressive phenotype of DC can be 
generated after 24 hours of treatment with IL-10.   
3.3.5 DC-derived exosomes contain costimulatory molecules 
Exosomes were purified from the supernatants of untreated and IL-10-treated DC 
cultures for analysis of costimulatory marker expression.  To analyze by FACS, exosomes were 
first absorbed onto anti-CD81 coated latex beads, and then stained with labeled antibodies to  
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Figure 14: Characterization of rIL10-treated tolerogenic DC. 
(A) DC were stained with PE-conjugated mAbs and analyzed by FACS.  Percent of positively stained cells 
was compared to isotype controls.  Results representative of four independent experiments.  * denotes 
significance at P≤0.05 of expression levels of IL-10 treated DC compared to non-treated controls.  (B) 10 µg of 
DC lysates were run on SDS-PAGE gels under non-reducing conditions and immunoblotted for B7-1, B7-2 or 
beta-actin as control.  NIH Image J was used to analyze protein band density.  (C) IL-10 treated and non-
treated DC were stimulated with 100ng/mL LPS overnight on day 7 of culture. Cytokine levels in culture 
supernatants were determined on day 8 using ELISA. Significance at p≤0.05 is represented on the figure by a 
single asterisk for DC.Non + LPS group compared to the other three groups, and double asterisk for the 
DC.IL-10+LPS group compared to the other three groups.  
Reprinted with permission from: Ruffner MA, Kim SH, Bianco NR, Francisco LM, Sharpe AH, Robbins PD. 
“B7-1/2, but not PD-L1/2 molecules, are required on tolerogenic DC and DC-derived exosomes for in vivo 
function.” European Journal of Immunology.  
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Figure 15: Characterization of exosomes from tolerogenic DC. 
Exosomes were purified from supernatant of control or rIL-10 treated DC.  (A) Anti-CD81 mAb was 
preabsorbed onto latex beads which were subsequently incubated with 10 µg of DC-derived exosomes. 
Samples were stained with PE-conjugated mAbs specific for IA/IE, H2kb, PD-L1, PD-L2, B7-1, and B7-2, or 
isotype control (represented by the open black line).  Results shown are representative of three independent 
experiments.  Percentage of beads containing positive signal, as well as MFI (in parentheses) are displayed.   
(B) 5 µg of exosomes were run on SDS-PAGE gels under non-reducing conditions and immunoblotted for B7-
1, B7-2 or CD9 as a loading control.  NIH Image J was used to analyze protein band density. 
Reprinted with permission from: Ruffner MA, Kim SH, Bianco NR, Francisco LM, Sharpe AH, Robbins PD. 
“B7-1/2, but not PD-L1/2 molecules, are required on tolerogenic DC and DC-derived exosomes for in vivo 
function.” European Journal of Immunology.  
 
 81 
MHC I (H-2kb), MHC II (IA/IE), B7-1, B7-2, PD-L1, and PD-L2 (Figure 2A).  We observe a 
significant decrease in the levels of PD-L1, PD-L2, and B7-1  on exosomes secreted by IL-10 
treated DC.  The decrease in the levels of B7-1 was confirmed by Western blot along with a 
decrease in the levels of B7-2 when compared to the level of the CD9 loading control (Figure 
2B). It has been demonstrated previously that exosomes secreted from mature DC are 
phenotypically and functionally different than those secreted by immature DC [17]. However, 
this is the first demonstration of phenotypic changes in the exosome population secreted by DC 
following treatment with cytokines to induce a tolerogenic phenotype.  Our data indicate that 
qualitative changes in costimulatory molecules levels on exosomes secreted by DC occur 
following treatment with IL-10, suggesting that the phenotypic response of DC to IL-10 
treatment is also seen in the exosomal compartment.  IL-10 treatment decreased the overall 
levels of MHCI, MHC II, B7-1, B7-2, and PD-L2 on the surface of the DC whereas the level of 
MHC II appears to increase on exosomes in contrast to the decrease in the levels of B7-1, B7-2, 
PD-L1, and PD-L2. 
3.3.6 In vivo therapeutic effects of IL-10 treated DC and exosomes require B7-1 and B7-2 
In the preceeding sections we have demonstrated that gene transfer of IDO to BMDC results in 
DC and DC-derived exosomes that are therapeutic in DTH and CIA models [180]. We also 
demonstrate that exosomes from DC transduced with a CTLA-4-Ig expressing adenoviral vector 
were suppressive in vivo in an IDO-dependent manner. As shown in Figure 13, loss of B7-1 and 
B7-2 significantly decreased the ability of exosomes from IDO-transduced DC to suppress 
inflammation in the DTH model. However, it is unclear if the requirement for B7-1 and B7-2 for 
in vivo efficacy of BMDC and DC-derived exosomes is related to the specific method of IDO 
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overexpression used to generate the suppressive DC and exosomes, or represents a more general 
phenomenon that can be generalized to other populations of suppressive DC and exosomes. 
Therefore, in the following experiments, we set out to determine if exosomes derived from IL-10 
treated DC also demonstrate a dependence on B7-1 and B7-2 for in vivo suppressive activity.   
As shown in Figures 14 and 15, DC and DC-derived exosomes normally contain both 
B7-1 and B7-2. To determine whether these are essential components for tolerogenic DC 
function, DC were isolated from B7-1-/-, B7-2-/-, or B7-1/B7-2-/- mice and treated with rIL-10 
or left untreated.  Exosomes were isolated from the enriched media.  IL-10 treated donor DC 
lacking B7-1 or B7-2, as well as the exosomes that they secrete, were significantly less effective 
at reducing paw swelling than the IL-10 treated wild-type controls (Figure 16A).  Although the 
therapeutic ability of the knockout exosomes were greatly reduced, we observed some remaining 
ability of exosomes from IL-10 treated knockout DC to reduce paw swelling by approximately 
20%.  A 20% reduction in paw swelling was also observed in mice receiving the IL-10 treated 
B7-2 -/- DC.    
These results demonstrate that both B7-1 and B7-2 are required on DC and DC-derived 
exosomes for reduction in inflammation in the DTH model.  This is consistent with data 
demonstrating that B7-1 and B7-2 on DC play critical roles in the generation of tolerance by 
interacting with CD4+CD25+ cells [203], altering effector T cell cytokine profiles [204], and 
regulating DC function through CTLA-4 signaling. Furthermore, the ability of the B7-2-/- DC to 
suppress the DTH response 20% more efficiently than DC lacking B7-1 is of interest given that 
B7-1 and B7-2 are known to play different roles in vivo [205, 206]. 
Given the reported suppressive functions of PD-L molecules, and our observation that levels of 
PD-L1 and PD-L2 on DC and DC-derived exosomes are regulated by IL-10 treatment, we  
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Figure 16: B7-1 and B7-2 are required on DC and DC-derived exosomes for therapeutic effect in the 
DTH model, whereas PD-L1 and PD-L2 are not. 
Wild-type C57BL/6 or knockout strain-derived DC were treated with rIL-10 or left untreated, and exosomes 
were isolated from the enriched media.  DC or exosomes were injected into the right hind footpad of KLH-
immunized wild-type mice simultaneously with KLH challenge to both hind footpads.  Dark bars = swelling 
post challenge in treated (right) paws, white bars = swelling in contralateral (left) untreated paws. (A) Loss of 
B7-1 or B7-2 on DC or DC-derived exosomes abrogates ability to suppress inflammation in the DTH model. 
**p≤0.001 for wild-type IL-10-treated DC and their secreted exosomes compared to all other groups.  
*p≤0.05, exosomes from IL-10-treated B7-1-/-, B7-2-/-, and double knockout DC conditions as compared to 
the wild type and their respective knockout untreated controls. B7-2-/- IL-10 treated DC are also significant 
at p≤0.05 compared to the B7-2-/- non-treated DC as well as the non-treated wild type DC.  (B) PD-L1 and 
PD-L2 are not required on DC and DC-derived exosomes for therapeutic effect in the DTH model. * p≤0.05 
for the treated paw of the IL-10-treated wild-type and PD-L DKO samples compared to controls.  There are 
no statistical differences between the wild-type and PD-L DKO IL-10 treated DC and exosome groups.   
Reprinted with permission from: Ruffner MA, Kim SH, Bianco NR, Francisco LM, Sharpe AH, Robbins PD. 
“B7-1/2, but not PD-L1/2 molecules, are required on tolerogenic DC and DC-derived exosomes for in vivo 
function.” European Journal of Immunology.  
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hypothesized that these molecules may also be required for DC and exosome function in the 
DTH model.  BMDC were generated from PD-L1/PD-L2-/- mice, treated with IL-10 or left 
untreated, were evaluated in the DTH model.  As shown in Figure 16B, IL-10 treated PD-L1/2-
deficient DC and their exosomes were still able to suppress inflammation compared with wild-
type DC and exosomes treated with IL-10. These results are consistent with data from bone 
marrow chimera studies that demonstrated expression of PD-L1 and PD-L2 on APC alone was 
not sufficient to ameliorate early-onset diabetes in PD-L1/PD-L2 -/- NOD mice [207]. 
3.4 CONCLUSIONS 
Our results indicate that adenoviral transduction of DC with an IDO- or CTLA-4-Ig expressing 
vectors are both efficient means to exogenously generate IDO-overexpressing DC.  These results 
with CTLA-4-Ig are consistent with those observed by others in the literature, as it has been 
previously reported that CTLA-4-Ig ligation of B7-1 or B7-2 on DC results in upregulation of 
IDO [208].  We further demonstrate that DC generated by either method produce exosomes that 
contain higher levels of IDO protein than untreated DC.  As the mechanisms of exosomes-
mediated signaling have not been fully elucidated, the functional significance of this finding is 
unclear.  Exogenous IDO within exosomes may function by delivering IDO to IDO deficient 
antigen presenting cells, or IDO+ exosomes may interact directly with T cells in a manner that is 
capable of depleting them of essential tryptophan or producing kynureines in these cells.  Studies 
have shown that IDO-mediated DC signaling to T cells results in suppression of effector CD8+ T 
cells and induction of a regulatory T cell population via GCN2-kinase dependent induction of 
FoxP3 in naïve CD4+CD25- cells [209, 210].  Although we detected production of L-kynurenine 
 85 
in the exosomes-free supernatants, we did not detect L-kynurenine in the exosomes, suggesting 
that delivery of tryptophan metabolites is not a mechanism whereby exosomes from IDO-
overexpresing cells confer suppression. 
We next determined the therapeutic efficacy of IDO-overexpressing DC and the 
exosomes they secrete in a DTH model of antigen-specific inflammation.  Our results indicate 
that both adenoviral transfer of IDO and CTLA-4 to DC result in a DC population capable of 
suppressing inflammation in the DTH model.  We have further demonstrated that these 
genetically-modified DC secrete exosomes which are as effective as their parental DC at 
decreasing paw swelling in DTH mice.  The IDO inhibitor 1-MT reduced the suppressive 
qualities of CTLA-4-Ig when added to DC culture, suggesting that the effects of CTLA-4-Ig 
transduction on the DC are dependent on IDO activity.  However, in these experiments 1-MT 
was removed before injection of DC or exosomes into the mice, which implies that there is a 
critical role for IDO on the DC themselves which render them capable of regulating 
inflammation during the ex vivo culture period.   
Therefore, we hypothesize that IDO-overexpression in the DC modifies them in some 
other way(s) to render them tolerogenic.  Specifically, we demonstrate a critical role for B7-1 
and B7-2 expression on the exosomes secreted by the IDO-overexpressing DC.  This result 
suggests that exosomes may directly interact with T cells in vivo, and is consistent with previous 
findings that exosomes require MHC II and FasL for in vivo activity in the DTH model [19].  As 
B7 signaling is known to induce IDO activity within the DC, B7 may only have be integral in 
supporting IDO mediated suppression of DTH in exosomes, but not in mediating signaling in 
other suppressive DCs.  Thus, we wanted to further explore the role of B7 using another type of 
suppressive exosome. 
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To do so, we first confirmed that IL-10 treatment generates a tolerogenic DC phenotype 
and demonstrated that IL-10 treated DC secrete a modified population of exosomes that contain 
decreased levels of B7-1, B7-2, PD-L1 and PD-L2 as compared to exosomes secreted by control 
DC.  This data regarding phenotypic difference between tolerogenic and control exosomes is of 
particular significance given the growing interest in exosomes for therapeutic applications, as it 
is critical to the immunomodulatory mechanisms of exosomes. Our data also demonstrate that 
the phenotypic changes seen after treatment with IL-10 on the cell surface of DC and on the 
exosomes secreted by DC are different.  This suggests that regulation of protein trafficking in 
these compartments differs, and may reflect an underlying difference in the physiologic role of 
DC and exosomes in vivo.    
Using the DTH model, we further demonstrate a requirement for B7-1 and B7-2, but not 
PD-L1 or PD-L2 for in vivo function of IL-10 treated DC and the tolerogenic exosomes they 
secrete.  This is consistent with our previous result demonstrating that B7-1 and B7-2 are 
partially required for in vivo function when suppressive DC and exosomes were generated using 
IDO gene transfer.  Taken together, these results suggest a critical role for B7-1/2 on DC and 
DC-derived exosomes in vivo, regardless of the method by which the therapeutic DC or 
exosomes are generated.   It is interesting to note, while B7 molecules are necessary to confer 
immunosuppressive qualities of exosomes, they are present in reduced levels on suppressive 
Exo/IL-10.  Thus, this supports the hypothesis that these molecules allow for interaction with 
endogenous T-cell populations, and promote tolerance when expressed at low levels.  
Our findings indicate that the majority of in vivo suppressive activity of exosomes is 
dependent on B7-1 and B7-2.  We do not observe any differences in the requirement for B7 
based on the method by which the suppressive DC are generated, as exosomes from IDO-
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overexpressing DC and IL-10 treated DC demonstrate similar loss of function when B7 knockout 
cells are used.  Our observations that exosomes require B7-1 and B7-2 for function in vivo are 
consistent with in vitro findings suggesting that both ICAM-1 and CD28/B7 molecules are 
critical for APC-derived membrane vesicles to directly activate T cells, but contradictory to 
findings that only ICAM-1, and not B7 molecules are required for exosomes to stimulate T-cell 
responses when mediated through DC uptake and representation [211, 212].  However, as yet it 
remains unclear whether the primary in vivo mechanism of exosomes is mediated through APC 
or involves direct interaction with T cells.  Likely, there are multiple mechanisms of significance 
by which exosomes act depending on the particular conditions.   While our results demonstrate 
the importance of both B7-1 and B7-2 molecules on exosomes for in vivo suppression of 
inflammation in the DTH model, in the B7 knockout conditions the exosomes from the IL-10 
treated or IDO-overexpressing knockout DC retain approximately 20% of their suppressive 
ability.  This suggests that while B7 signaling is highly important for the in vivo suppressive 
activity of exosomes, redundant mechanisms of exosome-host cell communication may be 
utilized to confer suppressive effects in vivo.  
3.5 MATERIALS AND METHODS 
3.5.1 Mice 
Female C57BL/6 (H-2Kb) and B7 knockout mice (B7-1/B7-2 -/- = B6.129S4-Cd80tm1Shr 
Cd86tm2Shr/J,  B7-1 -/- = B6.129S4-Cd80tm1Shr/J,  B7-2 -/- = B6.129S4-Cd86tm1Shr/J) were 
purchased at 7-8 weeks of age (Jackson Laboratory, Bar Harbor, ME).  PD-L1/PD-L2 -/- mice 
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have been previously described [207].  Mice were maintained in a pathogen-free facility 
according to institutional and National Institutes of Health (NIH) guidelines. 
3.5.2 Vector Construction and Adenovirus Generation 
Adenoviruses expressing murine IDO (Ad.IDO) and CTLA4-Ig (Ad.CTLA4-Ig) were 
constructed, propagated, and titered according to standard protocols as previously described 
[177].  Briefly, the recombinant adenoviruses were generated by homologous recombination in 
293 cells expressing Cre recombinase (CRE8 cells), after co-transfection of DNA, an adenovirus 
5-derived, E1- and E3-deleted adenoviral backbone (psi5) and pAdlox, the adenoviral shuttle 
vector.  The inserted cDNA sequences are expressed under the human CMV promoter.  The 
recombinant adenoviruses were purified by CsCl gradient ultracentrifugation, dialyzed in sterile 
virus storage buffer, aliquoted and stored at – 80oC until use.  The CRE8 cells were grown and 
maintained in DMEM (Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf 
serum.  
3.5.3 DC Generation 
Bone-marrow derived DC were prepared following a bulk-culture protocol modified from Son, et al. 
as previously described [179, 180]. Briefly, bone marrow was collected from tibias and femurs of 6- 
to 7-week-old mice.  Contaminating erythrocytes were lysed with ACK cell lysing buffer 
(Mediatech, Herdon, VA).  Monocytes were collected from the interface after centrifuging on 
Nycoprep (NycoMed, Roskilde, Denmark) at 600 x g for 20 min at RT.  Cells were cultured for 24 h 
in complete media (RPMI 1640 containing 10% FBS, 50 µM 2-β-Mercaptoethanol, 2 mM 
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glutamine, 0.1 mM nonessential amino acids, 100 IU/mL penicillin/streptomycin) to remove 
adherent macrophages.  Non-adherent cells were placed in fresh growth medial (complete media 
containing 1000 U/mls of GM-CSF and IL-4) to generate DC.  Cells were cultured for 4 days and 
harvested.   
3.5.4 Adenoviral infection of BMDC 
On day 5 of BMDC culture, 1 X 106 DC were mixed with 5 X 107 PFU of the viruses in 
total volume of 1 ml serum-free media. After a 2 hr incubation with virus, 10 ml complete media 
was added to the cells.  In certain experiments, the cells were also treated with 1-methyl-D-
tryptophan (1-MT)(Sigma)(200µM) or L-trp (245 µM) at this time.  After incubation for 24 hr, 
DC were washed intensively three times and cultured for a further 48 h.  On day 8, culture 
supernatant was collected for exosome purification and recovery of the Ad-transduced DC.  This 
infection method routinely gives us ~70-80% transfection efficiency using Ad.eGFP as a control 
[181].  There was no toxic effect of 1-MT or L-trp on the cells as observed by trypan blue 
exclusion and overall cell count. 
3.5.5 IL-10 treatment of BMDC 
On day 5 of BMDC culture, 1 X 107 DC were incubated for 2 hours with 1 µg/mL of the 
recombinant murine IL-10 (Cell Sciences, Canton, Massachusetts) in total volume of 1 mL serum-
free media, then diluted 1:5 in CM for further incubation.  After incubation for 12 hr, DC were 
washed three times in PBS and cultured for 48 h in growth media without rIL-10.  On day 8, culture 
supernatant was collected for exosome purification and DC recovery.  
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3.5.6 Exosome Isolation 
Exosome isolation procedure has previously been described [115].  Briefly, DC culture supernatants 
were collected and centrifuged at 300 g for 10 min, 1200 g for 20 min, and 10,000 g for 30 min, and 
then ultra-centrifuged at 100,000 g for 1 h.  Exosome pellet was washed in sterile PBS, centrifuged 
at 100,000 g for 1 h, and resuspended in 120 µl of PBS for further studies. Exosome batch protein 
content was quantified and standardized by a micro Bradford protein assay (Bio-Rad, CA). 1 µg 
exosomes were suspended in 20 µl of PBS for in vivo mouse studies. 
3.5.7 DTH Model 
Female C57BL/6 of 7-8 weeks of age were sensitized by injecting 100 µg of Keyhole Limpet 
Hemocyanin (KLH)  antigen emulsified 1:1 in CFA at a single dorsal site.  14 days later, the right 
hind footpad of immunized mice were injected with 106 DC or 1 µg of exosomes suspended in 50µL 
total volume PBS containing 20µg of KLH antigen.  Contra-lateral footpad received 50µL total 
volume PBS containing 20µg of KLH antigen, without any DC or exosomes. Footpad swelling was 
measured bilaterally using a spring-loaded caliper at 24, 48 and 72 hours after injection.  Results are 
expressed as the difference in swelling (X 0.01 mm), before and after Ag boost injection. 
Experiments were performed with 5 or 6 mice per group and repeated at least twice to ensure 
reproducibility. 
 91 
3.5.8 Western Blot Analysis 
For western blot, exosomal proteins (3-10µg) were separated by 12% or 15% SDS-PAGE, semi-
dry transferred onto PVDF and detected by western blotting using an enhanced 
chemiluminescence detection kit.  Primary antibodies used for western blot were: rabbit 
polyclonal anti-GFP (Santa Cruz), mouse monoclonal anti-hsc70 (Santa Cruz), rabbit polyclonal 
anti-beta actin (abcam), mouse monoclonal anti-IDO (Upstate), hamster monoclonal anti-B7-1 
(clone 16-10A1), rat monoclonal anti-CD9 (clone KCM8), (both from BD Pharmigen, San Jose, 
California), and rat monoclonal anti-B7-2 (clone GL1, R&D systems, Minneapolis, Minnesota).   
Semi-quantitative analysis of the protein density bands was performed using the NIH Image J 
program. 
3.5.9 Measurement of kynurenine concentrations 
Kynurenine was measured in exosomes (1 µg) or exosome-free supernatants (60µl) using a 
spectrophotometric assay.  Samples were mixed 2:1 with 30% trichloroacetic acid, vortexed, and 
centrifuged at 3716 x g for 10 minutes.  75µl of supernatant was then added to an equal volume 
of Ehrlich reagent (2% 4-(dimethylamino)benzaldehyde in glacial acetic acid) in a 96 well 
microtiter plate.  Samples (in triplicate) were analyzed against a standard curve of L-kynurenine 
(Sigma)(0-5 mM).  Absorbance was measured at 490nm using a microplate reader. 
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3.5.10 FACS Analysis 
Anti-CD81 labeled-latex beads were generated by incubating 250 uL of 4 µm latex beads 
overnight at 4° C in a solution containing 60 ug anti-CD81 mAb (EBioscience, San Diego, CA) 
and 250 µL BSA in MES buffer.  After washing beads three times in PBS, 10 µg of exosomes 
were incubated with 15 µL of the anti-CD81 labeled-latex beads in 500 uL of PBS.  Samples 
were centrifuged at 700g for 5 min, resuspended in ice-cold PBS containing goat serum and 
stained with 1-2 µL of PE-labeled Ab in 100 µL total volume.   
Dendritic cells were washed and stained with 1-2 µL of PE-labeled mAbs (B7.1 (16-
10A1), B7.2 (PO3.1), PD-L1 (MIH5), PD-L2 (TY25), IA-IE (M5/114.15.2), H2-kb (AF6-88.5), 
all from eBioscience, San Diego, CA) in 100 µL total volume of ice-cold PBS containing goat 
serum.  Exosome-coated beads and DC were washed twice in FACS buffer, resuspended in 400 
µL FACS buffer, and examined by FACS (FACScan, BD Biosciences, San Jose, CA).  Results 
were analyzed using WinMDI 2.9. 
3.5.11 ELISA 
Supernatants from LPS- and mock-stimulated BMDC were collected and analyzed using a 
sandwich ELISA to detect IL-23 (R&D systems, Minneapolis, Minnesota), IL-6, IL-12/IL-23 
total p40, and IL-12p70 (all from eBioscience, San Diego, CA) according to the manufacturer’s 
protocol.  The limits of detection were 2 pg/mL for IL-12/IL-23 total p40 , 4 pg/mL for both IL-6 
and IL-12p70, and 1 pg/mL for IL-23. 
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3.5.12 Statistics 
Results were compared by analysis of variance (ANOVA) with Fisher’s Least Significant 
Difference post-hoc test.   When appropriate, the Kruskal-Wallis non-parametric test was used to 
compare means between groups.  P values less than 0.05 were considered statistically significant, 
and all tests were conducted using SPSS statistical software (SPSS, Chicago IL). 
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4.0  GENERAL DISCUSSION 
4.1 SUMMARY 
Molecular, cellular, and organ engineering has grown in significance to become an important 
part of the field of bioengineering.  Although this is perhaps most obvious when one looks at the 
explosion of interest in the field of tissue engineering, where the goal is to regenerate an entire 
organ or tissue, its principles can nonetheless be employed to generate novel therapeutics at the 
single-cell, protein, or gene level.  It is a multi-disciplinary field that utilizes knowledge from 
medicine, molecular biology, genetics, and engineering design principles in order to manipulate 
the structure-function relationships of the biological target.  As our knowledge of cellular 
function has expanded, our ability to make purposeful modifications to cells has multiplied.  For 
example, the discovery of DNA in 1953 led rapidly to an increase in the knowledge of basic 
cellular functions, and paved the pathway to clinical trials of gene therapy techniques by the 
1990s [213].  The field is constantly incorporating new discoveries, as evidenced by the 
explosion of studies utilizing siRNA-targeted knockdown in the brief period of time following 
the description of the RNA-interference phenomena in 1998 [214].  
This studies described herein fall within the field of cellular engineering, and are 
similarly multi-disciplinary. A main goal of this work is to genetically engineer DC so that they 
are reprogrammed to down-regulate inflammation. Adenoviral gene transfer techniques have 
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been used to manipulate bone-marrow derived DC, and increase the expression of anti-
inflammatory genes, specifically IL-4, IDO, and CTLA-4-Ig, which confer tolerogenic 
properties.   
The data presented in Chapter 2 demonstrate that DC overexpressing IL-4 are able to 
reduce insulitis and prevent the onset of diabetes in NOD mice.  We observe an upregulation of 
FoxP3 in the pancreatic lymph node and an alteration in increase in the ratio of Th2 to Th1 
cytokine secretion by splenocytes following stimulation with islet antigens.  Taken together, 
these results imply that DC transduced to express IL-4 are capable of reestablishing peripheral 
tolerance in a proportion of the NOD mice.   These results are consistent with previously 
published observations examining the ability of DC transduced with IL-4-expressing gene 
therapy vectors to prevent diabetes onset in 5- and 10-week old , as well as 12-week old NOD 
mice [15, 72].  When using the NOD model, the age at which a therapy is tested is very 
important as a larger number of immunomodulatory therapies are able to prevent autoimmune 
diabetes when administered at early ages, whereas comparably few prevent disease onset if 
administered after 12-weeks of age [137].    
In Chapter 2, we report for the first time that DC transduced to express IL-4 are capable 
of preventing the onset of hyperglycemia when administered to NOD mice after they have 
developed prediabetes.  In our studies, mice were screened by random blood glucose 
measurement for the development of prediabetes, defined here as a repeat random blood glucose 
measurements between 150 and 250 mg/dL. These criteria differentiate mice with elevated 
baseline blood glucose and increased fluctuations in blood glucose [174].  We confirm that these 
mice demonstrate an impaired response to glucose challenge, with elevated peak levels and 
prolonged return to baseline blood glucose following administration of L-dextrose.  In the NOD 
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model this is indicative of islet dysfunction secondary to progressions in autoimmune diabetes.  
However, despite this advanced state of disease, a single i.v. administration of one million 
DC/sIL-4 resulted in significant protection from the disease progression and the onset of 
hyperglycemia. 
In chapter 3 we demonstrate that exogenous gene transfer of IDO to DC can be used to 
efficiently generate tolerogenic DC ex vivo.  Despite the known tolerogenic properties of IDO, 
few studies have examined exogenous gene transfer of IDO to DC.  Previous studies have shown 
that genetically-engineered IDO+ DC inhibit T cell responses in vitro [215], and prolong cardiac 
allograft survival following adoptive transfer in vivo [63].  Our results indicate that transduction 
with both an IDO adenoviral vector, as well as a CTLA-4-Ig expressing vector results in the 
production of IDO+ DC.  Following incubation with 1-MT, a specific IDO inhibitor, DC/CTLA-
4-Ig were no longer suppressive in vivo (data not shown), and the exosomes they secreted were 
no longer able to reduce paw swelling in the DTH model.   
However, there remains significant interest in the mechanisms whereby tolerogenic DC 
and exosomes regulate immune responses.  In particular, little is known regarding the nature of 
exosome signaling in vivo.  In Chapter 3, we address one aspect of these questions by examining 
the role of costimulatory molecules on our DC and exosomes.  We demonstrate that B7-1 and B-
72 are required on DC and exosomes for tolerogenic activity in the DTH model.  By examining 
exosomes secreted from IDO-transduced and rIL-10 treated DC, we conclude that this 
requirement for B7 is not dependent on the method used to generate the tolerogenic DC.  Further, 
we observe that exosomes lacking B7 molecules retain a reduced ability to decrease paw 
swelling in the DTH model, suggesting non-B7-dependent mechanism(s) of exosome-mediated 
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suppression in vivo.  Surprisingly, loss of PD-L1 and PD-L2 from DC and exosomes had little 
effect on their function, which was contrary to our initial expectations.   
4.2 CLOSING COMMENTS 
The results presented in this thesis lay the groundwork for future endeavors in multiple areas.  
We demonstrate the efficacy of DC transduced to express in IL-4 in prediabetic NOD mice, 
however, many patients are fully diabetic at the time of diagnosis.  Similarly, we demonstrate 
that generation of IDO+ DC using adenoviral vectors expressing IDO or CTLA-4-Ig is possible 
and can be used to reduce inflammation in DTH and collagen-induced arthritis [68]. Significant 
progress was made in examining gene transfer-based strategies for the development of 
tolerogenic DC and exosomes, however additional work will be required in preclinical models in 
order to determine their utility in treating human disease.  A first step forward would be to 
examine the ability of DC/sIL-4 to treat NOD mice with recent-onset hyperglycemia, as many 
patients have are similarly hyperglycemic at the time of diagnosis. 
Tolerance induction is a complex process, requiring the interaction of the proper cell 
types in the appropriate microenvironment and anatomical location.  The balance between 
tolerance and immunity is very sensitive and maintained by the interplay of all of these factors.  
In this work, we demonstrate a critical role for B7-1 and B7-2 expression on tolerogenic DC and 
exosomes for the function in vivo.  In itself, this is interesting as it runs contrary to the prevailing 
models of tolerogenic DC which postulate that tolerance induction is best achieved with DC with 
the lowest possible levels of B7 costimulatory molecules.  However, it also raises a series of 
questions as well.  Of particular interest is why exosomes have a B7 requirement, specifically, 
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which cells do they interact with and what are the effects of exosomal B7?  However, the small 
scale of exosomes compared to the limits of currently available technology make these difficult 
issues to pursue.   Nonetheless, this work suggests a role for both DC and exosomes in the 
induction of tolerance, and suggest that further investigation into their therapeutic applications 
for autoimmune disease such as type 1 diabetes are justified. 
 
 
 
 
 
 
 99 
BIBLIOGRAPHY 
1. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301-305. 
2. Fischer M, Ehlers M. Toll-like receptors in autoimmunity. Ann N Y Acad Sci 2008; 
1143: 21-34. 
3. Reis e Sousa C, Hieny S, Scharton-Kersten T, Jankovic D, Charest H, Germain RN, et al. 
In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin 
12 by dendritic cells and their redistribution to T cell areas. In: J Exp Med, vol. 186 1997:1819-
1829. 
4. Dalod M, Salazar-Mather TP, Malmgaard L, Lewis C, Asselin-Paturel C, Brière F, et al. 
Interferon alpha/beta and interleukin 12 responses to viral infections: pathways regulating 
dendritic cell cytokine expression in vivo. In: J Exp Med, vol. 195 2002:517-528. 
5. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F. Kinetics of dendritic cell 
activation: impact on priming of TH 1, TH 2 and nonpolarized T cells. In: Nat Immunol 2000. 
6. Sallusto F, Palermo B, Lenig D, Miettinen M. Distinct patterns and kinetics of chemokine 
production regulate dendritic cell function. In: European journal of immunology 1999. 
7. Ludewig B, Ehl S, Karrer U, Odermatt B, Hengartner H, Zinkernagel RM. Dendritic cells 
efficiently induce protective antiviral immunity. In: J Virol, vol. 72 1998:3812-3818. 
8. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, et al. Bone 
marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and 
therapeutic antitumour immunity. In: Nature medicine, vol. 1 1995:1297-1302. 
9. Maldonado-López R, De Smedt T, Michel P, Godfroid J, Pajak B, Heirman C, et al. 
CD8alpha+ and CD8alpha- subclasses of dendritic cells direct the development of distinct T 
helper cells in vivo. In: J Exp Med, vol. 189 1999:587-592. 
10. Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, et al. Rapid 
induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination 
with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. In: J Exp Med, 
vol. 195 2002:1279-1288. 
 100 
11. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, et al. Human 
epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. In: Nat 
Immunol, vol. 3 2002:673-680. 
12. Kyewski B, Klein L. A central role for central tolerance. Annu Rev Immunol 2006; 24: 
571-606. 
13. Bonasio R, Scimone ML, Schaerli P, Grabie N, Lichtman AH, von Andrian UH. Clonal 
deletion of thymocytes by circulating dendritic cells homing to the thymus. Nat Immunol 2006; 
7: 1092-1100. 
14. Adler HS, Steinbrink K. Tolerogenic dendritic cells in health and disease: friend and foe! 
Eur J Dermatol 2007; 17: 476-491. 
15. Feili-Hariri M, Falkner DH, Gambotto A, Papworth GD, Watkins SC, Robbins PD, et al. 
Dendritic cells transduced to express interleukin-4 prevent diabetes in nonobese diabetic mice 
with advanced insulitis. In: Hum Gene Ther, vol. 14 2003:13-23. 
16. Kim SH, Bianco NR, Shufesky WJ, Morelli AE, Robbins PD. Effective treatment of 
inflammatory disease models with exosomes derived from dendritic cells genetically modified to 
express IL-4. J Immunol 2007; 179: 2242-2249. 
17. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan 
catabolism. Nat Rev Immunol 2004; 4: 762-774. 
18. Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB, et al. Potential 
regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 
2002; 297: 1867-1870. 
19. Kim SH, Bianco NR, Shufesky WJ, Morelli AE, Robbins PD. MHC class II+ exosomes 
in plasma suppress inflammation in an antigen-specific and Fas ligand/Fas-dependent manner. J 
Immunol 2007; 179: 2235-2241. 
20. Sprent J. Direct stimulation of naïve T cells by antigen-presenting cell vesicles. In: Blood 
Cells Mol Dis, vol. 35 2005:17-20. 
21. Thomson AW, Robbins PD. Tolerogenic dendritic cells for autoimmune disease and 
transplantation. Ann Rheum Dis 2008; 67 Suppl 3: iii90-96. 
22. Scheinecker C, McHugh R, Shevach EM, Germain RN. Constitutive presentation of a 
natural tissue autoantigen exclusively by dendritic cells in the draining lymph node. J Exp Med 
2002; 196: 1079-1090. 
23. Huang FP, Platt N, Wykes M, Major JR, Powell TJ, Jenkins CD, et al. A discrete 
subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of 
mesenteric lymph nodes. J Exp Med 2000; 191: 435-444. 
 101 
24. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-
producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation 
with allogeneic immature human dendritic cells. J Exp Med 2000; 192: 1213-1222. 
25. Yamazaki S, Iyoda T, Tarbell K, Olson K, Velinzon K, Inaba K, et al. Direct expansion 
of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 
2003; 198: 235-247. 
26. Sato K, Yamashita N, Baba M, Matsuyama T. Modified myeloid dendritic cells act as 
regulatory dendritic cells to induce anergic and regulatory T cells. Blood 2003; 101: 3581-3589. 
27. Turnquist HR, Raimondi G, Zahorchak AF, Fischer RT, Wang Z, Thomson AW. 
Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but 
enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J 
Immunol 2007; 178: 7018-7031. 
28. Alegre ML, Fallarino F. Mechanisms of CTLA-4-Ig in tolerance induction. Curr Pharm 
Des 2006; 12: 149-160. 
29. Munn DH, Sharma MD, Mellor AL. Ligation of B7-1/B7-2 by human CD4+ T cells 
triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol 2004; 172: 4100-
4110. 
30. Mellor AL, Chandler P, Baban B, Hansen AM, Marshall B, Pihkala J, et al. Specific 
subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-
mediated induction of indoleamine 2,3 dioxygenase. Int Immunol 2004; 16: 1391-1401. 
31. Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr 
Top Microbiol Immunol 2006; 311: 17-58. 
32. Lu L, Lee WC, Takayama T, Qian S, Gambotto A, Robbins PD, et al. Genetic 
engineering of dendritic cells to express immunosuppressive molecules (viral IL-10, TGF-beta, 
and CTLA4Ig). J Leukoc Biol 1999; 66: 293-296. 
33. Volkmann A, Zal T, Stockinger B. Antigen-presenting cells in the thymus that can 
negatively select MHC class II-restricted T cells recognizing a circulating self antigen. J 
Immunol 1997; 158: 693-706. 
34. Brocker T, Riedinger M, Karjalainen K. Targeted expression of major histocompatibility 
complex (MHC) class II molecules demonstrates that dendritic cells can induce negative but not 
positive selection of thymocytes in vivo. J Exp Med 1997; 185: 541-550. 
35. Oberholzer C, Tschoeke SK, Bahjat K, LaFace D, Hutchins B, Clare-Salzler MJ, et al. In 
vivo transduction of thymic dendritic cells with adenovirus and its potential use in acute 
inflammatory diseases. Scand J Immunol 2005; 61: 309-315. 
 102 
36. Oluwole SF, Jin MX, Chowdhury NC, Engelstad K, Ohajekwe OA, James T. Induction 
of peripheral tolerance by intrathymic inoculation of soluble alloantigens: evidence for the role 
of host antigen-presenting cells and suppressor cell mechanism. Cell Immunol 1995; 162: 33-41. 
37. Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: cytokine modulation comes of 
age. Blood 2006; 108: 1435-1440. 
38. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant 
tolerance. Nat Rev Immunol 2007; 7: 610-621. 
39. Levings MK, Bacchetta R, Schulz U, Roncarolo MG. The role of IL-10 and TGF-beta in 
the differentiation and effector function of T regulatory cells. Int Arch Allergy Immunol 2002; 
129: 263-276. 
40. Buelens C, Willems F, Delvaux A, Piérard G, Delville JP, Velu T, et al. Interleukin-10 
differentially regulates B7-1 (CD80) and B7-2 (CD86) expression on human peripheral blood 
dendritic cells. In: Eur J Immunol, vol. 25 1995:2668-2672. 
41. Faulkner L, Buchan G, Baird M. Interleukin-10 does not affect phagocytosis of 
particulate antigen by bone marrow-derived dendritic cells but does impair antigen presentation. 
In: Immunology, vol. 99 2000:523-531. 
42. Allavena P, Piemonti L, Longoni D, Bernasconi S, Stoppacciaro A, Ruco L, et al. IL-10 
prevents the differentiation of monocytes to dendritic cells but promotes their maturation to 
macrophages. Eur J Immunol 1998; 28: 359-369. 
43. Allavena P, Piemonti L, Longoni D, Bernasconi S, Stoppacciaro A, Ruco L, et al. IL-10 
prevents the generation of dendritic cells from CD14+ blood monocytes, promotes the 
differentiation to mature macrophages and stimulates endocytosis of FITC-dextran. Adv Exp 
Med Biol 1997; 417: 323-327. 
44. Faunce DE, Terajewicz A, Stein-Streilein J. Cutting edge: in vitro-generated tolerogenic 
APC induce CD8+ T regulatory cells that can suppress ongoing experimental autoimmune 
encephalomyelitis. J Immunol 2004; 172: 1991-1995. 
45. Belladonna ML, Volpi C, Bianchi R, Vacca C, Orabona C, Pallotta MT, et al. Cutting 
edge: Autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells. J 
Immunol 2008; 181: 5194-5198. 
46. Penna G, Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, 
maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell 
activation. J Immunol 2000; 164: 2405-2411. 
47. Griffin MD, Xing N, Kumar R. Gene expression profiles in dendritic cells conditioned by 
1alpha,25-dihydroxyvitamin D3 analog. J Steroid Biochem Mol Biol 2004; 89-90: 443-448. 
 103 
48. Gonzalez-Rey E, Chorny A, Fernandez-Martin A, Ganea D, Delgado M. Vasoactive 
intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 
regulatory T cells. Blood 2006; 107: 3632-3638. 
49. Delgado M, Gonzalez-Rey E, Ganea D. The neuropeptide vasoactive intestinal peptide 
generates tolerogenic dendritic cells. J Immunol 2005; 175: 7311-7324. 
50. Adorini L, Giarratana N, Penna G. Pharmacological induction of tolerogenic dendritic 
cells and regulatory T cells. Semin Immunol 2004; 16: 127-134. 
51. Matsue H, Yang C, Matsue K, Edelbaum D, Mummert M, Takashima A. Contrasting 
impacts of immunosuppressive agents (rapamycin, FK506, cyclosporin A, and dexamethasone) 
on bidirectional dendritic cell-T cell interaction during antigen presentation. J Immunol 2002; 
169: 3555-3564. 
52. Hackstein H, Thomson AW. Dendritic cells: emerging pharmacological targets of 
immunosuppressive drugs. Nat Rev Immunol 2004; 4: 24-34. 
53. Woltman AM, de Fijter JW, Kamerling SW, Paul LC, Daha MR, van Kooten C. The 
effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells. 
Eur J Immunol 2000; 30: 1807-1812. 
54. Yang J, Bernier SM, Ichim TE, Li M, Xia X, Zhou D, et al. LF15-0195 generates 
tolerogenic dendritic cells by suppression of NF-kappaB signaling through inhibition of IKK 
activity. J Leukoc Biol 2003; 74: 438-447. 
55. Wang GY, Chen GH, Li H, Huang Y, Wang GS, Jiang N, et al. Rapamycin-treated 
mature dendritic cells have a unique cytokine secretion profile and impaired allostimulatory 
capacity. Transpl Int 2009. 
56. Xu H, Zhang Y, Hua Y, Chen T, Wang H, Wu W. IL-12 p35 silenced dendritic cells 
modulate immune responses by blocking IL-12 signaling through JAK-STAT pathway in T 
lymphocytes. Biochem Biophys Res Commun 2007; 353: 812-816. 
57. Hill JA, Ichim TE, Kusznieruk KP, Li M, Huang X, Yan X, et al. Immune modulation by 
silencing IL-12 production in dendritic cells using small interfering RNA. J Immunol 2003; 171: 
691-696. 
58. Giannoukakis N, Bonham CA, Qian S, Chen Z, Peng L, Harnaha J, et al. Prolongation of 
cardiac allograft survival using dendritic cells treated with NF-kB decoy 
oligodeoxyribonucleotides. Mol Ther 2000; 1: 430-437. 
59. Kanagawa N, Koretomo R, Murakami S, Sakurai F, Mizuguchi H, Nakagawa S, et al. 
Factors involved in the maturation of murine dendritic cells transduced with adenoviral vector 
variants. Virology 2008; 374: 411-420. 
60. Krieg AM. Direct immunologic activities of CpG DNA and implications for gene 
therapy. J Gene Med 1999; 1: 56-63. 
 104 
61. Morelli AE, Larregina AT, Ganster RW, Zahorchak AF, Plowey JM, Takayama T, et al. 
Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent 
pathway. J Virol 2000; 74: 9617-9628. 
62. Newton KR, Sala-Soriano E, Varsani H, Stephenson JR, Goldblatt D, Wedderburn LR. 
Human dendritic cells infected with an adenoviral vector suppress proliferation of autologous 
and allogeneic T cells. Immunology 2008; 125: 469-479. 
63. Li J, Meinhardt A, Roehrich ME, Golshayan D, Dudler J, Pagnotta M, et al. Indoleamine 
2,3-dioxygenase gene transfer prolongs cardiac allograft survival. Am J Physiol Heart Circ 
Physiol 2007; 293: H3415-3423. 
64. Newland A, Kireta S, Russ G, Krishnan R. Ovine dendritic cells transduced with an 
adenoviral CTLA4eEGFP fusion protein construct induce hyporesponsiveness to allostimulation. 
Immunology 2004; 113: 310-317. 
65. Dufter C, Watzlik A, Christ C, Jung M, Wirzbach A, Opelz G, et al. Suppression of T-
cell alloreactivity by gene-therapeutic modulation of human dendritic stimulator cells with TGF-
beta adenoviral vectors. Transplant Proc 2001; 33: 190-191. 
66. Lu L, Gambotto A, Lee WC, Qian S, Bonham CA, Robbins PD, et al. Adenoviral 
delivery of CTLA4Ig into myeloid dendritic cells promotes their in vitro tolerogenicity and 
survival in allogeneic recipients. Gene Ther 1999; 6: 554-563. 
67. Kim SH, Bianco N, Menon R, Lechman ER, Shufesky WJ, Morelli AE, et al. Exosomes 
derived from genetically modified DC expressing FasL are anti-inflammatory and 
immunosuppressive. In: Mol Ther, vol. 13 2006:289-300. 
68. Bianco NR, Kim SH, Morelli AE, Robbins PD. Modulation of the immune response 
using dendritic cell-derived exosomes. In: Methods Mol Biol, vol. 380 2007:443-455. 
69. Takayama T, Morelli AE, Robbins PD, Tahara H, Thomson AW. Feasibility of CTLA4Ig 
gene delivery and expression in vivo using retrovirally transduced myeloid dendritic cells that 
induce alloantigen-specific T cell anergy in vitro. Gene Ther 2000; 7: 1265-1273. 
70. Takayama T, Nishioka Y, Lu L, Lotze MT, Tahara H, Thomson AW. Retroviral delivery 
of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity 
and promotes the induction of T-cell hyporesponsiveness. Transplantation 1998; 66: 1567-1574. 
71. Dresch C, Edelmann SL, Marconi P, Brocker T. Lentiviral-mediated transcriptional 
targeting of dendritic cells for induction of T cell tolerance in vivo. J Immunol 2008; 181: 4495-
4506. 
72. Creusot RJ, Yaghoubi SS, Kodama K, Dang DN, Dang VH, Breckpot K, et al. Tissue-
targeted therapy of autoimmune diabetes using dendritic cells transduced to express IL-4 in NOD 
mice. In: Clin Immunol, vol. 127 2008:176-187. 
 105 
73. Jenne L, Hauser C, Arrighi JF, Saurat JH, Hugin AW. Poxvirus as a vector to transduce 
human dendritic cells for immunotherapy: abortive infection but reduced APC function. Gene 
Ther 2000; 7: 1575-1583. 
74. Willis RA, Bowers WJ, Turner MJ, Fisher TL, Abdul-Alim CS, Howard DF, et al. 
Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate 
antitumor immunity in mice. Hum Gene Ther 2001; 12: 1867-1879. 
75. Rogers JV, Bigley NJ, Chiou HC, Hull BE. Targeted delivery of DNA encoding herpes 
simplex virus type-1 glycoprotein D enhances the cellular response to primary viral challenge. 
Arch Dermatol Res 2000; 292: 542-549. 
76. Bros M, Wiechmann N, Besche V, Castor T, Sudowe S, Grabbe S, et al. A novel plasmid 
DNA electroporation method allows transfection of murine DC. J Immunol Methods 2009; 343: 
13-20. 
77. Machen J, Harnaha J, Lakomy R, Styche A, Trucco M, Giannoukakis N. Antisense 
oligonucleotides down-regulating costimulation confer diabetes-preventive properties to 
nonobese diabetic mouse dendritic cells. J Immunol 2004; 173: 4331-4341. 
78. Ma L, Qian S, Liang X, Wang L, Woodward JE, Giannoukakis N, et al. Prevention of 
diabetes in NOD mice by administration of dendritic cells deficient in nuclear transcription 
factor-kappaB activity. Diabetes 2003; 52: 1976-1985. 
79. Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during 
reticulocyte maturation. Association of plasma membrane activities with released vesicles 
(exosomes). J Biol Chem 1987; 262: 9412-9420. 
80. Thery C, Regnault A, Garin J, Wolfers J, Zitvogel L, Ricciardi-Castagnoli P, et al. 
Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the 
heat shock protein hsc73. J Cell Biol 1999; 147: 599-610. 
81. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, et al. B 
lymphocytes secrete antigen-presenting vesicles. J Exp Med 1996; 183: 1161-1172. 
82. Al-Nedawi K, Szemraj J, Cierniewski CS. Mast cell-derived exosomes activate 
endothelial cells to secrete plasminogen activator inhibitor type 1. Arterioscler Thromb Vasc 
Biol 2005; 25: 1744-1749. 
83. van Niel G, Raposo G, Candalh C, Boussac M, Hershberg R, Cerf-Bensussan N, et al. 
Intestinal epithelial cells secrete exosome-like vesicles. Gastroenterology 2001; 121: 337-349. 
84. Mears R, Craven RA, Hanrahan S, Totty N, Upton C, Young SL, et al. Proteomic 
analysis of melanoma-derived exosomes by two-dimensional polyacrylamide gel electrophoresis 
and mass spectrometry. Proteomics 2004; 4: 4019-4031. 
85. Rialland P, Lankar D, Raposo G, Bonnerot C, Hubert P. BCR-bound antigen is targeted 
to exosomes in human follicular lymphoma B-cells. Biol Cell 2006; 98: 491-501. 
 106 
86. Hegmans JP, Bard MP, Hemmes A, Luider TM, Kleijmeer MJ, Prins JB, et al. Proteomic 
analysis of exosomes secreted by human mesothelioma cells. Am J Pathol 2004; 164: 1807-
1815. 
87. Caby MP, Lankar D, Vincendeau-Scherrer C, Raposo G, Bonnerot C. Exosomal-like 
vesicles are present in human blood plasma. Int Immunol 2005; 17: 879-887. 
88. Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in 
human urine. Proc Natl Acad Sci U S A 2004; 101: 13368-13373. 
89. Admyre C, Grunewald J, Thyberg J, Gripenback S, Tornling G, Eklund A, et al. 
Exosomes with major histocompatibility complex class II and co-stimulatory molecules are 
present in human BAL fluid. Eur Respir J 2003; 22: 578-583. 
90. Andre F, Schartz NE, Movassagh M, Flament C, Pautier P, Morice P, et al. Malignant 
effusions and immunogenic tumour-derived exosomes. Lancet 2002; 360: 295-305. 
91. Bard MP, Hegmans JP, Hemmes A, Luider TM, Willemsen R, Severijnen LA, et al. 
Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am J Respir 
Cell Mol Biol 2004; 31: 114-121. 
92. Thery C, Boussac M, Veron P, Ricciardi-Castagnoli P, Raposo G, Garin J, et al. 
Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment 
distinct from apoptotic vesicles. J Immunol 2001; 166: 7309-7318. 
93. Taylor DD, Akyol S, Gercel-Taylor C. Pregnancy-associated exosomes and their 
modulation of T cell signaling. J Immunol 2006; 176: 1534-1542. 
94. Abusamra AJ, Zhong Z, Zheng X, Li M, Ichim TE, Chin JL, et al. Tumor exosomes 
expressing Fas ligand mediate CD8+ T-cell apoptosis. Blood Cells Mol Dis 2005; 35: 169-173. 
95. Zhang HG, Liu C, Su K, Yu S, Zhang L, Zhang S, et al. A membrane form of TNF-alpha 
presented by exosomes delays T cell activation-induced cell death. J Immunol 2006; 176: 7385-
7393. 
96. Sabapatha A, Gercel-Taylor C, Taylor DD. Specific isolation of placenta-derived 
exosomes from the circulation of pregnant women and their immunoregulatory consequences. 
Am J Reprod Immunol 2006; 56: 345-355. 
97. Lee HS, Jeong J, Lee KJ. Characterization of vesicles secreted from insulinoma NIT-1 
cells. J Proteome Res 2009; 8: 2851-2862. 
98. Gutwein P, Stoeck A, Riedle S, Gast D, Runz S, Condon TP, et al. Cleavage of L1 in 
exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells. Clin Cancer 
Res 2005; 11: 2492-2501. 
 107 
99. Zhou H, Pisitkun T, Aponte A, Yuen PS, Hoffert JD, Yasuda H, et al. Exosomal Fetuin-A 
identified by proteomics: a novel urinary biomarker for detecting acute kidney injury. Kidney Int 
2006; 70: 1847-1857. 
100. Lotvall J, Valadi H. Cell to cell signalling via exosomes through esRNA. Cell Adh Migr 
2007; 1: 156-158. 
101. Mack M, Kleinschmidt A, Bruhl H, Klier C, Nelson PJ, Cihak J, et al. Transfer of the 
chemokine receptor CCR5 between cells by membrane-derived microparticles: a mechanism for 
cellular human immunodeficiency virus 1 infection. Nat Med 2000; 6: 769-775. 
102. MacKenzie A, Wilson HL, Kiss-Toth E, Dower SK, North RA, Surprenant A. Rapid 
secretion of interleukin-1beta by microvesicle shedding. Immunity 2001; 15: 825-835. 
103. Denzer K, van Eijk M, Kleijmeer MJ, Jakobson E, de Groot C, Geuze HJ. Follicular 
dendritic cells carry MHC class II-expressing microvesicles at their surface. J Immunol 2000; 
165: 1259-1265. 
104. Morelli AE, Larregina AT, Shufesky WJ, Sullivan ML, Stolz DB, Papworth GD, et al. 
Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood 2004; 
104: 3257-3266. 
105. Segura E, Guerin C, Hogg N, Amigorena S, Thery C. CD8+ dendritic cells use LFA-1 to 
capture MHC-peptide complexes from exosomes in vivo. J Immunol 2007; 179: 1489-1496. 
106. Veron P, Segura E, Sugano G, Amigorena S, Thery C. Accumulation of MFG-
E8/lactadherin on exosomes from immature dendritic cells. Blood Cells Mol Dis 2005; 35: 81-
88. 
107. Miyanishi M, Tada K, Koike M, Uchiyama Y, Kitamura T, Nagata S. Identification of 
Tim4 as a phosphatidylserine receptor. Nature 2007; 450: 435-439. 
108. Nolte-'t Hoen EN, Buschow SI, Anderton SM, Stoorvogel W, Wauben MH. Activated T 
cells recruit exosomes secreted by dendritic cells via LFA-1. Blood 2009; 113: 1977-1981. 
109. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, et al. Eradication of 
established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat 
Med 1998; 4: 594-600. 
110. Bedford P, Garner K, Knight SC. MHC class II molecules transferred between allogeneic 
dendritic cells stimulate primary mixed leukocyte reactions. Int Immunol 1999; 11: 1739-1744. 
111. Karlsson M, Lundin S, Dahlgren U, Kahu H, Pettersson I, Telemo E. "Tolerosomes" are 
produced by intestinal epithelial cells. Eur J Immunol 2001; 31: 2892-2900. 
112. Andreola G, Rivoltini L, Castelli C, Huber V, Perego P, Deho P, et al. Induction of 
lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 2002; 
195: 1303-1316. 
 108 
113. Martinez-Lorenzo MJ, Anel A, Gamen S, Monle n I, Lasierra P, Larrad L, et al. 
Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles. J 
Immunol 1999; 163: 1274-1281. 
114. Kim SH, Bianco N, Menon R, Lechman ER, Shufesky WJ, Morelli AE, et al. Exosomes 
derived from genetically modified DC expressing FasL are anti-inflammatory and 
immunosuppressive. Mol Ther 2006; 13: 289-300. 
115. Kim SH, Lechman ER, Bianco N, Menon R, Keravala A, Nash J, et al. Exosomes derived 
from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J 
Immunol 2005; 174: 6440-6448. 
116. http://www.cdc.gov/diabetes/projects/cda2.htm. In: Accessed April 13, 2009. 
117. Incidence and trends of childhood Type 1 diabetes worldwide 1990-1999. Diabet Med 
2006; 23: 857-866. 
118. Mathis D, Vence L, Benoist C. beta-Cell death during progression to diabetes. Nature 
2001; 414: 792-798. 
119. Yoon JW, Jun HS. Autoimmune destruction of pancreatic beta cells. Am J Ther 2005; 12: 
580-591. 
120. Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N 
Engl J Med 1994; 331: 1428-1436. 
121. LeRoith D. Treatment of diabetes: a clinical update on insulin trials. Clin Cornerstone 
2007; 8: 21-29; discussion 30-22. 
122. Butler DA, Zuehlke JB, Tovar A, Volkening LK, Anderson BJ, Laffel LM. The impact of 
modifiable family factors on glycemic control among youth with type 1 diabetes. Pediatr 
Diabetes 2008; 9: 373-381. 
123. Marzorati S, Pileggi A, Ricordi C. Allogeneic islet transplantation. Expert Opin Biol Ther 
2007; 7: 1627-1645. 
124. van der Windt DJ, Bottino R, Casu A, Campanile N, Cooper DK. Rapid loss of 
intraportally transplanted islets: an overview of pathophysiology and preventive strategies. 
Xenotransplantation 2007; 14: 288-297. 
125. Meloche RM. Transplantation for the treatment of type 1 diabetes. World J Gastroenterol 
2007; 13: 6347-6355. 
126. Pasquali L, Giannoukakis N, Trucco M. Induction of immune tolerance to facilitate beta 
cell regeneration in type 1 diabetes. Adv Drug Deliv Rev 2008; 60: 106-113. 
127. Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by beta cell regeneration. J 
Clin Invest 2007; 117: 2553-2561. 
 109 
128. Gandhi GY, Murad MH, Flynn DN, Elamin MB, Erwin PJ, Montori VM, et al. 
Immunotherapeutic agents in type 1 diabetes: a systematic review and meta-analysis of 
randomized trials. Clin Endocrinol (Oxf) 2008; 69: 244-252. 
129. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, et al. 
A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in 
improvement in C-peptide responses and clinical parameters for at least 2 years after onset of 
type 1 diabetes. Diabetes 2005; 54: 1763-1769. 
130. Xiu Y, Wong CP, Bouaziz JD, Hamaguchi Y, Wang Y, Pop SM, et al. B lymphocyte 
depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite 
isotype-specific differences in Fc gamma R effector functions. J Immunol 2008; 180: 2863-2875. 
131. O'Neill S K, Liu E, Cambier JC. Change you can B(cell)eive in: recent progress confirms 
a critical role for B cells in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2009. 
132. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 
2002; 346: 1685-1691. 
133. Harrison LC, Honeyman MC, Steele CE, Stone NL, Sarugeri E, Bonifacio E, et al. 
Pancreatic beta-cell function and immune responses to insulin after administration of intranasal 
insulin to humans at risk for type 1 diabetes. Diabetes Care 2004; 27: 2348-2355. 
134. Ludvigsson J, Faresjo M, Hjorth M, Axelsson S, Cheramy M, Pihl M, et al. GAD 
treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008; 359: 1909-
1920. 
135. Ludvigsson J, Faresjo M, Hjorth M, Axelsson S, Cheramy M, Pihl M, et al. GAD 
treatment and insulin secretion in recent-onset type 1 diabetes. In: N Engl J Med, vol. 359 
2008:1909-1920. 
136. Shoda LK, Young DL, Ramanujan S, Whiting CC, Atkinson MA, Bluestone JA, et al. A 
comprehensive review of interventions in the NOD mouse and implications for translation. 
Immunity 2005; 23: 115-126. 
137. Roep BO, Atkinson M, von Herrath M. Satisfaction (not) guaranteed: re-evaluating the 
use of animal models of type 1 diabetes. In: Nature Reviews Immunology 2004. 
138. Lo J, Clare-Salzler MJ. Dendritic cell subsets and type I diabetes: focus upon DC-based 
therapy. Autoimmun Rev 2006; 5: 419-423. 
139. Lund T, Strid J. Is lack of peripheral tolerance induction a cause for diabetes in the non-
obese diabetic mouse? Arch Immunol Ther Exp (Warsz) 2000; 48: 405-416. 
140. Strid J, Lopes L, Marcinkiewicz J, Petrovska L, Nowak B, Chain BM, et al. A defect in 
bone marrow derived dendritic cell maturation in the nonobesediabetic mouse. Clin Exp 
Immunol 2001; 123: 375-381. 
 110 
141. Weaver DJ, Jr., Poligone B, Bui T, Abdel-Motal UM, Baldwin AS, Jr., Tisch R. 
Dendritic cells from nonobese diabetic mice exhibit a defect in NF-kappa B regulation due to a 
hyperactive I kappa B kinase. J Immunol 2001; 167: 1461-1468. 
142. Grohmann U, Fallarino F, Bianchi R, Orabona C, Vacca C, Fioretti MC, et al. A defect in 
tryptophan catabolism impairs tolerance in nonobese diabetic mice. J Exp Med 2003; 198: 153-
160. 
143. Eibl N, Spatz M, Fischer GF, Mayr WR, Samstag A, Wolf HM, et al. Impaired primary 
immune response in type-1 diabetes: results from a controlled vaccination study. Clin Immunol 
2002; 103: 249-259. 
144. Perone MJ, Bertera S, Tawadrous ZS, Shufesky WJ, Piganelli JD, Baum LG, et al. 
Dendritic cells expressing transgenic galectin-1 delay onset of autoimmune diabetes in mice. J 
Immunol 2006; 177: 5278-5289. 
145. Ma L, Qian S, Liang X, Wang L, Woodward JE, Giannoukakis N, et al. Prevention of 
diabetes in NOD mice by administration of dendritic cells deficient in nuclear transcription 
factor-kappaB activity. In: Diabetes, vol. 52 2003:1976-1985. 
146. Giannoukakis N, Phillips B, Trucco M. Toward a cure for type 1 diabetes mellitus: 
diabetes-suppressive dendritic cells and beyond. Pediatr Diabetes 2008; 9: 4-13. 
147. Kobayashi K, Kaneda K, Kasama T. Immunopathogenesis of delayed-type 
hypersensitivity. Microsc Res Tech 2001; 53: 241-245. 
148. Kalish RS, Askenase PW. Molecular mechanisms of CD8+ T cell-mediated delayed 
hypersensitivity: implications for allergies, asthma, and autoimmunity. J Allergy Clin Immunol 
1999; 103: 192-199. 
149. Strobel S. Immunologically mediated damage to the intestinal mucosa. Acta Paediatr 
Scand Suppl 1990; 365: 46-57. 
150. Cua DJ, Hinton DR, Kirkman L, Stohlman SA. Macrophages regulate induction of 
delayed-type hypersensitivity and experimental allergic …. In: European journal of immunology 
1995. 
151. Morikawa Y, Furotani M, Kuribayashi K, Matsuura N, Kakudo K. The role of antigen-
presenting cells in the regulation of delayed-type hypersensitivity. I. Spleen dendritic cells. In: 
Immunology, vol. 77 1992:81-87. 
152. Morikawa Y, Furotani M, Matsuura N, Kakudo K. The role of antigen-presenting cells in 
the regulation of delayed-type hypersensitivity. II. Epidermal Langerhans' cells and peritoneal 
exudate macrophages. In: Cell Immunol, vol. 152 1993:200-210. 
153. Cher DJ, Mosmann TR. Two types of murine helper T cell clone. II. Delayed-type 
hypersensitivity is mediated by TH1 clones. J Immunol 1987; 138: 3688-3694. 
 111 
154. Fong TA, Mosmann TR. The role of IFN-gamma in delayed-type hypersensitivity 
mediated by Th1 clones. J Immunol 1989; 143: 2887-2893. 
155. Issekutz TB, Stoltz JM. Lymphocyte recruitment in delayed-type hypersensitivity. The 
role of IFN-gamma. In: The Journal of Immunology 1988. 
156. Magram J, Connaughton SE, Warrier RR, Carvajal DM. IL-12-deficient mice are 
defective in IFNg production and type 1 cytokine responses. In: Immunity 1996. 
157. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu 
Rev Immunol 2005; 23: 447-485. 
158. Rodacki M, Milech A, de Oliveira JE. NK cells and type 1 diabetes. Clin Dev Immunol 
2006; 13: 101-107. 
159. Cameron MJ, Arreaza GA, Zucker P, Chensue SW, Strieter RM, Chakrabarti S, et al. IL-
4 prevents insulitis and insulin-dependent diabetes mellitus in nonobese diabetic mice by 
potentiation of regulatory T helper-2 cell function. J Immunol 1997; 159: 4686-4692. 
160. Rehman KK, Trucco M, Wang Z, Xiao X, Robbins PD. AAV8-mediated gene transfer of 
interleukin-4 to endogenous beta-cells prevents the onset of diabetes in NOD mice. Mol Ther 
2008; 16: 1409-1416. 
161. Angelini F, Del Duca E, Piccinini S, Pacciani V, Rossi P, Manca Bitti ML. Altered 
phenotype and function of dendritic cells in children with type 1 diabetes. Clin Exp Immunol 
2005; 142: 341-346. 
162. Mollah ZU, Pai S, Moore C, O'Sullivan BJ, Harrison MJ, Peng J, et al. Abnormal NF-
kappa B function characterizes human type 1 diabetes dendritic cells and monocytes. J Immunol 
2008; 180: 3166-3175. 
163. Allen JS, Pang K, Skowera A, Ellis R, Rackham C, Lozanoska-Ochser B, et al. 
Plasmacytoid dendritic cells are proportionally expanded at diagnosis of type 1 diabetes and 
enhance islet autoantigen presentation to T-cells through immune complex capture. Diabetes 
2009; 58: 138-145. 
164. Calderon B, Suri A, Miller MJ, Unanue ER. Dendritic cells in islets of Langerhans 
constitutively present beta cell-derived peptides bound to their class II MHC molecules. Proc 
Natl Acad Sci U S A 2008; 105: 6121-6126. 
165. Tang Q, Adams JY, Tooley AJ, Bi M, Fife BT, Serra P, et al. Visualizing regulatory T 
cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol 2006; 7: 83-92. 
166. Proudfoot O, Pouniotis D, Sheng KC, Loveland BE, Pietersz GA. Dendritic cell 
vaccination. Expert Rev Vaccines 2007; 6: 617-633. 
 112 
167. Zhong L, Granelli-Piperno A, Choi Y, Steinman RM. Recombinant adenovirus is an 
efficient and non-perturbing genetic vector for human dendritic cells. Eur J Immunol 1999; 29: 
964-972. 
168. King C, Mueller Hoenger R, Malo Cleary M, Murali-Krishna K, Ahmed R, King E, et al. 
Interleukin-4 acts at the locus of the antigen-presenting dendritic cell to counter-regulate 
cytotoxic CD8+ T-cell responses. Nat Med 2001; 7: 206-214. 
169. Rapoport MJ, Bistritzer T, Aharoni D, Weiss M, Ramot Y, Buchs A, et al. TH1/TH2 
cytokine secretion of first degree relatives of T1DM patients. Cytokine 2005; 30: 219-227. 
170. Hill NJ, Van Gunst K, Sarvetnick N. Th1 and Th2 pancreatic inflammation differentially 
affects homing of islet-reactive CD4 cells in nonobese diabetic mice. J Immunol 2003; 170: 
1649-1658. 
171. Papaccio G, Pisanti FA, Montefiano RD, Graziano A, Latronico MV. Th1 and Th2 
cytokines exert regulatory effects upon islet microvascular areas in the NOD mouse. J Cell 
Biochem 2002; 86: 651-664. 
172. Gagnerault MC, Luan JJ, Lotton C, Lepault F. Pancreatic lymph nodes are required for 
priming of beta cell reactive T cells in NOD mice. J Exp Med 2002; 196: 369-377. 
173. Roep BO, Atkinson M, von Herrath M. Satisfaction (not) guaranteed: re-evaluating the 
use of animal models of type 1 diabetes. Nat Rev Immunol 2004; 4: 989-997. 
174. Klueh U, Liu Z, Cho B, Ouyang T, Feldman B, Henning TP, et al. Continuous glucose 
monitoring in normal mice and mice with prediabetes and diabetes. Diabetes Technol Ther 2006; 
8: 402-412. 
175. Tan PH, Beutelspacher SC, Xue SA, Wang YH, Mitchell P, McAlister JC, et al. 
Modulation of human dendritic-cell function following transduction with viral vectors: 
implications for gene therapy. Blood 2005; 105: 3824-3832. 
176. Skapenko A, Kalden JR, Lipsky PE, Schulze-Koops H. The IL-4 receptor alpha-chain-
binding cytokines, IL-4 and IL-13, induce forkhead box P3-expressing CD25+CD4+ regulatory 
T cells from CD25-CD4+ precursors. J Immunol 2005; 175: 6107-6116. 
177. Kim SH, Evans CH, Kim S, Oligino T, Ghivizzani SC, Robbins PD. Gene therapy for 
established murine collagen-induced arthritis by local and systemic adenovirus-mediated 
delivery of interleukin-4. Arthritis Res 2000; 2: 293-302. 
178. Kim SH, Kim S, Evans CH, Ghivizzani SC, Oligino T, Robbins PD. Effective treatment 
of established murine collagen-induced arthritis by systemic administration of dendritic cells 
genetically modified to express IL-4. In: J Immunol, vol. 166 2001:3499-3505. 
179. Son YI, Egawa S, Tatsumi T, Redlinger RE, Jr., Kalinski P, Kanto T. A novel bulk-
culture method for generating mature dendritic cells from mouse bone marrow cells. J Immunol 
Methods 2002; 262: 145-157. 
 113 
180. Bianco NR, Kim SH, Ruffner MA, Robbins PD. Therapeutic effect of exosomes from 
indoleamine 2,3-dioxygenase-positive dendritic cells in collagen-induced arthritis and delayed-
type hypersensitivity disease models. Arthritis Rheum 2009; 60: 380-389. 
181. Kim SH, Kim S, Oligino TJ, Robbins PD. Effective treatment of established mouse 
collagen-induced arthritis by systemic administration of dendritic cells genetically modified to 
express FasL. Mol Ther 2002; 6: 584-590. 
182. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev 
Immunol 2003; 21: 685-711. 
183. Hegmans JP, Gerber PJ, Lambrecht BN. Exosomes. Methods Mol Biol 2008; 484: 97-
109. 
184. Admyre C, Johansson SM, Paulie S, Gabrielsson S. Direct exosome stimulation of 
peripheral human T cells detected by ELISPOT. Eur J Immunol 2006; 36: 1772-1781. 
185. Sprent J. Direct stimulation of naive T cells by antigen-presenting cell vesicles. Blood 
Cells Mol Dis 2005; 35: 17-20. 
186. Peche H, Heslan M, Usal C, Amigorena S, Cuturi MC. Presentation of donor major 
histocompatibility complex antigens by bone marrow dendritic cell-derived exosomes modulates 
allograft rejection. Transplantation 2003; 76: 1503-1510. 
187. Thery C, Duban L, Segura E, Veron P, Lantz O, Amigorena S. Indirect activation of 
naive CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol 2002; 3: 1156-1162. 
188. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, et al. Prevention 
of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281: 1191-1193. 
189. Katz JB, Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in T-cell tolerance 
and tumoral immune escape. Immunol Rev 2008; 222: 206-221. 
190. Schroecksnadel K, Winkler C, Duftner C, Wirleitner B, Schirmer M, Fuchs D. 
Tryptophan degradation increases with stage in patients with rheumatoid arthritis. Clin 
Rheumatol 2006; 25: 334-337. 
191. Brandacher G, Margreiter R, Fuchs D. Clinical relevance of indoleamine 2,3-dioxygenase 
for alloimmunity and transplantation. Curr Opin Organ Transplant 2008; 13: 10-15. 
192. Lob S, Konigsrainer A, Schafer R, Rammensee HG, Opelz G, Terness P. Levo- but not 
dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 2008; 
111: 2152-2154. 
193. King NJ, Thomas SR. Molecules in focus: indoleamine 2,3-dioxygenase. Int J Biochem 
Cell Biol 2007; 39: 2167-2172. 
 114 
194. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, et al. GCN2 kinase in T 
cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-
dioxygenase. Immunity 2005; 22: 633-642. 
195. Belladonna ML, Grohmann U, Guidetti P, Volpi C, Bianchi R, Fioretti MC, et al. 
Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional 
IDO. J Immunol 2006; 177: 130-137. 
196. Keir ME, Sharpe AH. The B7/CD28 costimulatory family in autoimmunity. Immunol 
Rev 2005; 204: 128-143. 
197. Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, et al. CTLA-4-Ig 
regulates tryptophan catabolism in vivo. Nat Immunol 2002; 3: 1097-1101. 
198. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and 
immunity. Annu Rev Immunol 2008; 26: 677-704. 
199. Kuipers H, Muskens F, Willart M, Hijdra D, van Assema FB, Coyle AJ, et al. 
Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell 
activation. Eur J Immunol 2006; 36: 2472-2482. 
200. Faulkner L, Buchan G, Baird M. Interleukin-10 does not affect phagocytosis of 
particulate antigen by bone marrow-derived dendritic cells but does impair antigen presentation. 
Immunology 2000; 99: 523-531. 
201. Buelens C, Willems F, Delvaux A, Pierard G, Delville JP, Velu T, et al. Interleukin-10 
differentially regulates B7-1 (CD80) and B7-2 (CD86) expression on human peripheral blood 
dendritic cells. Eur J Immunol 1995; 25: 2668-2672. 
202. Segura E, Amigorena S, Thery C. Mature dendritic cells secrete exosomes with strong 
ability to induce antigen-specific effector immune responses. Blood Cells Mol Dis 2005; 35: 89-
93. 
203. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, et al. B7/CD28 
costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that 
control autoimmune diabetes. Immunity 2000; 12: 431-440. 
204. Freeman GJ, Boussiotis VA, Anumanthan A, Bernstein GM, Ke XY, Rennert PD, et al. 
B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 
preferentially costimulates the initial production of IL-4. Immunity 1995; 2: 523-532. 
205. Lenschow DJ, Ho SC, Sattar H, Rhee L, Gray G, Nabavi N, et al. Differential effects of 
anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the 
nonobese diabetic mouse. J Exp Med 1995; 181: 1145-1155. 
206. Xiang J, Gu X, Qian S, Chen Z. Graded function of CD80 and CD86 in initiation of T-
cell immune response and cardiac allograft survival. Transpl Int 2008; 21: 163-168. 
 115 
207. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, et al. Tissue 
expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 2006; 203: 883-895. 
208. Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, et al. CTLA-4-Ig 
regulates tryptophan catabolism in vivo. In: Nat Immunol, vol. 3 2002:1097-1101. 
209. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, et al. Tryptophan 
catabolism generates autoimmune-preventive regulatory T cells. Transpl Immunol 2006; 17: 58-
60. 
210. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, et al. The 
combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell 
receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006; 176: 
6752-6761. 
211. Hwang I, Shen X, Sprent J. Direct stimulation of naive T cells by membrane vesicles 
from antigen-presenting cells: distinct roles for CD54 and B7 molecules. Proc Natl Acad Sci U S 
A 2003; 100: 6670-6675. 
212. Segura E, Nicco C, Lombard B, Veron P, Raposo G, Batteux F, et al. ICAM-1 on 
exosomes from mature dendritic cells is critical for efficient naive T-cell priming. Blood 2005; 
106: 216-223. 
213. Watson JD, Crick FH. Molecular structure of nucleic acids; a structure for deoxyribose 
nucleic acid. Nature 1953; 171: 737-738. 
214. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific 
genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-
811. 
215. Funeshima N, Fujino M, Kitazawa Y, Hara Y, Hayakawa K, Okuyama T, et al. Inhibition 
of allogeneic T-cell responses by dendritic cells expressing transduced indoleamine 2,3-
dioxygenase. J Gene Med 2005; 7: 565-575. 
 
 
